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“The significant problems we have cannot be solved at the same level of thinking 
with which we created them”.  
- Albert Einstein 
 
 

  
ABSTRACT 
The oxygen level inside cells, determine the amount of HIF protein. By directly being 
involved in HIF protein turnover rates, through a mechanism, by which, oxygen is 
utilized as a co-factor, for the PHD enzymes, regulating HIF protein stability. This 
allows for rapid stabilization of the HIFs and subsequent gene activation during low 
oxygen tensions inside cells.  
 
I investigated the role of HIF specific epigenetic effects, in cancer cell line models, 
as well as primary mouse CD8+ T-lymphocytes. The data in Paper I illustrates how 
HIF has the ability to modulate chromatin through a HIF-1α dependent chromatin 
remodeling event, in hypoxia responsive gene promoters. We were able to show 
how, during hypoxic incubations of cancer cell line models HepG2 and SK-N-Be(2)c, 
hypoxia target gene promoters were remodeled, removing auxiliary factors bound to 
DNA. Possibly giving access to transcription factor binding. We identified two 
separate nucleosome free regions (NFRs) in hypoxia target genes, inducible NFRs 
and constitutive NFRs. The latter, were characterized by no initial remodeling event 
during hypoxia, conversely, the inducible NFRs required HIF-1α for remodeling to 
occur. 
 
In Paper II we sought to identify the isoform specific effects of HIF-1α and HIF-2α in 
mouse primary CD8+ T-lymphocytes. We observed that HIF-1α was necessary for 
proper T-cell activation and cytotoxic function, by using mouse tumor xenograft 
models, showing decreased tumor size control in HIF-1α knockout T-cells. In 
contrast, HIF-2α knockout T-cells, activated properly, and controlled tumor size as 
well as control cells. VEGFA, a known HIF-1α target gene, conditional knockout in 
T-lymphocytes, showed increased tumor growth, in xenograft studies, as well, 
increased chemotherapeutic response. This finding, illustrates the complex nature 
of the tumor microenvironment, the role of the HIFα isoforms, as well as, VEGFA´s 
role in modulating tumor vessels and the ability for chemotherapeutics to be 
successfully delivered.  
 
It has been shown that T-lymphocytes accumulated 2-hydroxyglutaric acid 
stereoisomers R/S-2HG in a HIF-1α dependent fashion. Were S-2HG, have 
important biological roles for CD8+ T-cell function. In Paper III we identified the 
epigenetic effects of S-2HG during T-cell activation ex vivo, by following epigenetic 
modification changes through time. Our findings, illustrate how S-2HG metabolite 
decreases the overall acetylation of histone tails, at the histone 3 lysine 9 mark. The 
acetylation of histone proteins, has been widely studied, and is associated with 
increases in gene transcription. The global decreases in histone acetylation, 
observed by exogenous administration of S-2HG, might be a plausible mechanism 
for how, T-lymphocytes change their epigenome during activation.  
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ODD oxygen dependent degradation domain  
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R-2HG R-2-Hydroxyglutaric acid  
  
RAD51  RAD51 Recombinase 
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S-2HG S-2-Hydroxyglutaric acid  
SAM S-adenosylmethionine  
SEM stem cell effector 
SLC2A1 (Glut1) Solute Carrier Family 2 Member 1 
SWI/SNF switching sucrose non-fermenting  
TAM tumor associated macrophages  
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TCR T-cell receptor  
VEGFA Vascular Endothelial Growth Factor A 
VHL von Hippel-Lindau  
  
  
  
  

  7 
1 INTRODUCTION 
 
To generate the necessary energy demanded for an organism, molecular oxygen 
(O2) has been utilized as the primary fuel for adenosine triphosphate (ATP) 
production in the respiratory chain of the mitochondrion. When levels of O2 are in 
sufficient amounts for chemical reactions to occur, cells and tissues will function 
properly, however, when the supply of O2 is less than the demand, a state of hypoxia 
will occur. At normal physiology, oxygenation in tissues will vary, for example during 
exercise skeletal muscle oxygen tension will decrease (Lundby, Calbet and Robach, 
2009), and lactic acid will be produces as a consequence.  
 
Numerous pathologies are associated with a state of hypoxia, such as stroke, 
ischemia, and cancer (Semenza, 2014; Schito and Semenza, 2016). Lack of oxygen 
in these tissues and cells leads to a more severe outcome. Tumors are often 
characterized by hypoxia, an impaired vasculature, and aerobic glycolysis (Hanahan 
and Weinberg, 2011). Tumors are also very heterogenous and patient specific, 
which leads to an even more complex depiction of the role tumor hypoxia has within 
a given tumor. In hepatocellular carcinoma (HCC), one of the most common liver 
cancers with a low 5 year survival rate (Siegel, Miller and Jemal, 2018), hypoxic 
tumors are correlated to a less favorable outcome, by being involved in 
angiogenesis, metabolic deregulation, sustaining proliferation, and activating 
metastatic growth. (Chen et al., 2017). In childhood tumors like neuroblastoma, 
hypoxia has been shown to initiate a genetical program towards a more immature 
phenotype (Jogi et al., 2002; Axelson et al., 2005). In neuroblastoma tumor 
xenografts, hypoxia induced gene upregulation of sympathetic neural progenitor 
genes, such as c-kit and Notch-1, while down-regulated neuronal neuroendocrine 
genes. As with most solid tumors, the less differentiated a tumor is, the more 
malignant it can become (Oskarsson, Batlle and Massagué, 2014). 
 
Tissue hypoxia has been shown to occur in inflamed tissues such as inflammatory 
bowel disease (IBD) (Taylor and Colgan, 2017). Furthermore, the link between T 
lymphocytes and hypoxia, as well as components of the hypoxia pathway is growing 
ever clearer. For instance, VHL deletions in early thymocytes, resulted in smaller 
thymus due to a severe reduction in CD4/CD8-double positive thymocytes, due to 
apoptosis (Biju et al., 2004). Interestingly, further deletion of HIF-1α in the VHL 
knockout background, restored the thymocyte development and prevented 
excessive apoptosis (Biju et al., 2004), suggesting a role for the hypoxia pathway in 
thymocyte development. The cellular response to hypoxia is mainly mediated 
through two transcription factors, hypoxia inducible factor 1 alpha (HIF-1α) and HIF-
2α encoded by the genes HIF1A and EPAS1 respectively. The aforementioned 
physiological or pathological hypoxic conditions are either directly or indirectly 
affecting HIFα or mediated through HIFα protein function.  
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HIFΑ PROTEIN STABILITY  
 
Cellular response to hypoxia is driven by a family of transcription factors, HIF-1α, 
HIF-2α and HIF-3α, they belong to the PER-ARNT-SIM (PAS) family (Wang et al., 
1995) of the basic helix-loop-helix (bHLH) transcription factors, illustrated in Fig. 1. 
HIFα is continuously expressed at the mRNA level, however the protein products are 
tightly regulated in the presence of O2 through post-translational hydroxylation and 
polyubiquitination of target residues present in HIFα proteins. A family of prolyl 
hydroxylase domain containing proteins (PHD-1-3), hydroxylate HIF-1α on proline 
residue 402 and 564 (Ivan et al., 2001; Jaakkola et al., 2001), while HIF-2α is 
hydroxylated at proline residues 402 and 531. Hydroxylation of these key residues 
mediates binding of protein von Hippel-Lindau (pVHL), an E3 ubiquitin ligase, 
targeting HIFα for proteasomal degradation by the 26s proteasome (Huang et al., 
1998; Kallio et al., 1999; Maxwell et al., 1999) in the presence of O2. Additional 
hydroxylation takes place on the C-terminal transactivation domain of HIFα proteins 
by factor inhibiting HIF-1 (FIH-1). This asparaginyl hydroxylation is added on 
asparagine 803 and 847 on HIF-1α and HIF-2α respectively (Lando, Peet, Whelan, 
et al., 2002). The effect off FIH-1 hydroxylation during physiological oxygen tension 
has been shown to affect HIFα protein transactivation activity by inhibiting the 
interaction of p300/CBP binding proteins (Mahon, Hirota and Semenza, 2001; 
Lando, Peet, Gorman, et al., 2002). Collectively the protein domain where 
hydroxylation as well as ubiquitination (Maxwell et al., 1999), occurs on HIFα 
proteins has been appropriately termed oxygen dependent degradation domain 
(ODD), highlighting the oxygen sensitive protein turnover of the HIFα proteins. 
 
 During hypoxia, the PHD enzymes are limited in substrate availability of oxygen, 
leading to stabilization of HIFα protein, nuclear translocation and heterodimerization 
with the oxygen insensitive binding partner aryl hydrocarbon receptor nuclear 
translocator (ARNT) or HIF-1β (Jiang et al., 1996). HIFα/HIFβ heterodimers bind to 
their cognate DNA binding sequence, hypoxia response element (HRE), in the 
nucleus, 5´- R/C-GTG -´3, were R is either adenine or guanine DNA bases, and 
induce gene transcription of target genes.  
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Fig 1. Schematic representation of human HIFα protein structures.  (A) HIF-1α protein 
schematic, illustrated are protein domains of interest. Basic helix loop helix (bHLH) DNA 
binding domain, Per-Arnt-Sim (PAS), dimerization domain with binding partners. Oxygen 
degradation domain (ODD), herein lies the necessary proline residues which are 
hydroxylated by PHD enzymes for degradation. Nuclear localization signal (NLS), necessary 
for nuclear import. C-terminal transactivation domain (CTAD), transactivation domain for 
HIF-1α protein, as well as, FIH asparagine hydroxylation site. (B) HIF-2α protein schematic, 
illustrating the protein domains of interest. (C) HIF-3α protein schematic, multiple HIF-3α 
isoforms exist, chosen here is the HIF-3α-1 protein schematic containing the leucine zipper 
(LZIP) domain. (D) ARNT or HIF-1β protein schematic, illustrating the important protein 
domains, of interest, HIF-1β has no ODD protein domain, therefore is thought of as being 
oxygen insensitive. (E) Regulation of HIFα through PHD and FIH hydroxylation, as well as, 
VHL polyubiquitination. Degradation occurs at the 26s proteasome. (F) During low oxygen 
conditions, oxygen is limited, therefore, PHDs and FIH, will hydroxylate at lower rates, which 
enables stabilization of HIFα proteins, nuclear translocation, binding to HIF-1β with 
subsequent DNA transactivation. 
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1.1  HIFΑ GENE REGULATION   
 
HIFα target gene regulation has been extensively studied in the past two decades. 
Pioneering work from Wang,GL et al., (Wang and Semenza, 1993), described how 
in Hep3B cells, a hepatoma cancer cell line, HIF-1α during hypoxia was stabilized 
and bound to the 3´enhancer of the erythropoietin (EPO) gene. The messenger 
ribonucleic acid (mRNA) of both HIF-1α and EPO genes were elevated during 
hypoxia, which gave insights into the notion that HIF-1α stability and de novo 
transcription of the HIF1A gene itself were required for optimal HIF response.  
 
 HIFα target genes can be characterized into two groups, the glycolytic genes 
(GLUT1, HK1, HK2, PGK1, ALDH2 and LDHA), and the angiogenesis genes (ADM1, 
VEGFA and EPO) (Ryan et al., 1998; Hu et al., 2003; Keith, Johnson and Simon, 
2011), the upregulation of these genes is usually ascribed to HIF-1α function, 
although both HIF-1α and HIF-2α bind the same HRE sequences, shown through 
ChIP-seq data in cell line model MCF-7. Were HIF-1α and HIF-2α bound DNA is 
pulled down, together with HIF-1β antibody. And true HIFα peaks were determined 
only when sufficient amounts of HIF-1α/β or HIF-2α/β peaks were overlapping. 
(Schödel et al., 2011). The authors could show that both HIFα isoforms, bind to the 
core motif, RCGTG, and no discernable difference could be shown.  
 
The difference in target gene specificity could partially be explained by the fact that 
EPAS1 is not expressed as widely as HIF-1α (Tian, McKnight and Russell, 1997). 
However, upon closer examination, EPAS1 mRNA and protein could be detected in 
several rat organs after hypoxic incubation (WIESENER et al., 2002). Elucidating 
which gene is regulated by which isoform is therefore more complex than the mere 
presence of the protein product. The biological evidence of HIFα isoform non-
redundancy is highlighted by the different knockout mice models that have been 
generated. HIF-1α deficient mice die at embryonic day 10.5 displaying cardiac 
malformations, vascular regression and impaired erythropoiesis (Iyer, Leung and 
Semenza, 1998), however HIF-2α knockout mice survive until embryonic day 9.5 to 
12.5 with severe vascular phenotypes, suggesting a more vascular role for HIF-2α 
protein function (Peng et al., 2000).  
 
The third HIFα isoform HIF-3α, is regulated by oxygen availability inside the cells 
through the PHD-pVHL system (Maynard et al., 2003), and expressed in a multitude 
of organs such as, kidney, heart, thymus, lung and brain (Gu et al., 1998). HIF-3α 
has been shown to act as a negative regulator of HIF-1α through posttranscriptional 
splice variants generating inhibitory pas protein (IPAS) (Makino et al., 2001). HIF-3α 
splice variants have been shown to be HIF-1α regulated during hypoxia and might 
have important hypoxic modulatory roles in different tissues (Tanaka et al., 2009).  
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1.1.1 Epigenetic regulation of transcription  
 
It is arguably one of the most important features of a cell to be able to accurately 
increase certain protein products at demand to maximize survival advantage. The 
process of transcription which involves a complex machinery of protein-complexes, 
can be initiated through mitotic signals, as well as cytoplasmic/nuclear signaling. All 
cells have the ability to respond to their environment, although not all signals will 
lead to gene activation, however, during hypoxic insults, cells will rapidly stabilize 
HIFα which has the capacity to initiate gene transcription.  
 
Despite HIFα´s propensity to bind DNA, it is not the only determinant of successful 
transcription initiation, like all other transcription factors it faces the accessibility 
problem. The DNA in eukaryotic cells is wrapped around 4 core histone proteins as 
shown in Fig. 2. Namely, histone 2A (H2A), histone 2B (H2B), histone 3 (H3) and 
histone 4 (H4), they form what is called the nuclear core particle (NCP), which was 
successfully crystalized two decades ago (Luger et al., 1997). The core proteins are 
bound together as tetramers H2A-H2B and H3-H4, with two tetramers connecting 
together to form the nucleosome. DNA is wrapped around the NCP at around 146 
base pairs (bp) (Talbert and Henikoff, 2017), generating what is called the beads on 
a string chromatin. In between nucleosomes lays histone 1 (H1), which is even called 
the linker histone. The function of H1 has been proposed to range from chromatin 
compaction, to transcription efficiency (Bell et al., 2011; Rhee et al., 2014). DNA 
compaction is one of the ways cells modulate transcriptional output, the best-known 
examples of transcriptional regulation at the packaging level is described as 
euchromatin and heterochromatin. Heterochromatin is divided into two forms, 
constitutive heterochromatin are regions in the genome that are transcriptionally 
silent, such as the centromere and telomere, the silent rRNA genes and the majority 
of the transposable elements (Politz, Scalzo and Groudine, 2013), facultative 
heterochromatin are silent genomic regions that are gene rich. Which have the ability 
to re-activate transcription (Chen and Dent, 2014). These heterochromatic areas are 
often found to have H3 lysine 9 mono, di, and tri methylation (H3K9me1/2/3) 
modifications as well as heavy DNA methylation (Swygert and Peterson, 2014). The 
unpacked, transcriptionally active genome is termed euchromatin, which has been 
associated with acetylation modifications on histone N-terminal tails on lysine 9 and 
27 of H3 (H3K9/27Ac), methylation modifications on lysine 4 and 36, phosphorylation 
on serine 10 on H3 as well as many other modifications (Venkatesh and Workman, 
2015).   
 
The post-translational modifications (PTMs) of histone N-terminal tails are another 
mechanism regulating transcription initiation, from yeast to human cells, these highly 
conserved PTMs, with some species differences, have been extensively studied 
(Waterborg, 2012; Woo and Li, 2012). An emerging hypothesis trying to explain how 
the addition or removal of methyl or acetyl-groups on histone proteins could have 
effects on such a complex mechanism as transcription, is that these modifications 
are read by other proteins, that recognize these modifications and bind to them 
(Braun et al., 2017). Methylation recognizing protein motifs are termed 
chromodomains first described 2001 (Bannister et al., 2001), acetylation recognizing 
motifs are termed bromodomains (Dhalluin et al., 1999). The chromodomain of 
heterochromatin binding protein 1α (HP1α) was shown to be specifically binding 
H3K9me and was shown to not have as high affinity towards H3K4me. The binding 
of HP1α is thought to sustain heterochromatin regions. Analogously to the 
chromodomain, the bromodomain of Gcn5, an HAT acetylating H3K9/14, was shown 
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to have site specificity as well (Cieniewicz et al., 2014). These motifs are found in 
many different protein complexes, with different affinities for said modification. HIFα 
has been shown to regulate both JMJD1a as well as G9a, two opposing histone 
protein PTM erasers and writers of H3K9me2 respectively. Germ cell derived 
tumors, such as seminomas, yolk sac tumors and embryonal carcinomas, were 
shown to downregulate JMJD1a, which was unsurprisingly not necessary for stem-
cell renewal, however served as a tumor suppressor, acting as a counter balance to 
the hypoxia driven expression of G9a (Ueda et al., 2014). Loss of JMJD1a in this 
context, generated larger tumors, while pharmacological inhibition of G9a generated 
reduced tumor size in nude mice supporting the notion that G9a expression through 
HIFα could be oncogenic.  
 
HAT enzymes use acetyl-CoA as their substrate for acetylation of histone tails, 
conversely, histone methyltransferases (HMTs) use S-adenosylmethionine (SAM) 
as the major methyl donor. The link between the cells metabolic output and 
epigenetic function is beginning to emerge (Li et al., 2018). To date, 550 histone 
PTMs have been found through mass spectrometry and increased refinement of 
these techniques (Andrews, Strahl and Kutateladze, 2016), however the vast 
majority of these modifications have not yet been ascribed to any biological process.  
In the nucleus, the DNA is positioned according to activity, being closer to the nuclear 
periphery in highly compacted states as heterochromatin anchored through lamin-
associated domains (LADs) (Towbin et al., 2012). These subnuclear DNA 
rearrangements were ascribed to different methylation states of H3K9me through 
stepwise addition of methylated lysine residues, in Caenorhabditis elegans embryos 
(Towbin et al., 2012). The physical movement of DNA is also occurring on the 
nucleosomal level, by a family of nucleosome remodelers termed SWI/SNF (in 
humans BAF). These complexes have been implicated in numerous physiological 
processes, cell cycle progression (Dunaief et al., 1994), T-cell CD4+/CD8+ reciprocal 
regulation (Chi et al., 2002), neural development (Tang, Yoo and Crabtree, 2013) 
and cancer (Wang, Haswell and Roberts, 2014). Encompassing a whooping 30 
genes in the BAF family, with the ability to assemble in multiple combinations 
generates many a complexes with cell type specific expression patterns, creating 
tissue specific BAFs (Lessard and Crabtree, 2010).  These complexes use the 
energy of ATP hydrolysis to evict nucleosomes, reshuffle them as well reposition 
them during transcription, interacting with transcription factors in a cell type specific 
manner (Ho et al., 2011). The study of nucleosome eviction, mapping regulatory 
sites in the genome, such as nucleosome free regions (NFRs) has been aided with 
the help of enzymes that have the ability to shred or cut DNA. DNase I has been 
widely used to map regulatory sites in the genome and coupled with next generation 
sequencing enable full genome wide identification of DNase hypersensitivity sites 
(DHS) (John et al., 2013).  
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Fig 2. Schematic representation of the NCP with DNA wrapped around. Highlighted PTM 
modifications. The nuclear core particle (NCP) contains the 4 canonical histone proteins, 
namely H2A-H2B, H3 and H4, bound together as tetramers, to form the octamer NCP. 
Wrapped around and in between the histones, is roughly 146 base pairs of DNA. Histone 
post-translation modifications are added covalently to their respective N-terminal protruding 
tails, by numerous enzyme families.  
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1.2 HIFΑ EPIGENETIC REGULATION  
 
The core activation complex of HIFα/HIFβ is augmented by its co-activator 
p300/CBP (Arany et al., 1996; Kallio et al., 1998). The p300/CBP complex functions 
as a histone acetyltransferase (HAT), adding acetylation moieties to histone lysine 
N-terminal tails. The acetylation of histones has long been associated with increased 
transcriptional activity (Sabari et al., 2016). For over a decade, HIFα has been shown 
to bind to HRE sequences at target gene promoters that are affecting epigenetical 
readouts in a cell dependent manner. For instance, the histone deacetylase 7 
(HDAC-7) protein has been shown to act as a binding partner of HIF-1α (Kato, 
Tamamizu-Kato and Shibasaki, 2004), even under normoxic conditions in HEK293 
cells. During hypoxia, HDAC-7 would translocate to the nucleus, and form a complex 
with HIF-1α and p300, increasing target gene expression (Kato, Tamamizu-Kato and 
Shibasaki, 2004). Moreover, histone methylation of histone 3 lysine 9 (H3K9me), 
mediated through G9a/GLP enzyme, was shown to increase in hypoxia, in several 
cell line models (Chen et al., 2006). H3K9me2, which is highly correlated to low 
transcriptional output, was increased in hypoxia, at Mlh1 and Dhfr genes (Chen et 
al., 2006), as well as global levels of H3K9me2 was observed to increase during 
hypoxia, which was abrogated in G9a-/- mouse embryonic stem cells. The converse 
reaction of removing methylation from histones, mediated by histone demethylases, 
has been shown to be HIF-1α dependent (Beyer et al., 2008). Through hypoxia 
incubations of cell line models, JMJD1a and JMJD2a mRNA were increased in a 
hypoxia dependent fashion. Furthermore, the authors could show by ChIP-qPCR 
analysis, how HIF-1α was associated with HRE sequences present in the proximal 
promoters of these gene loci (Beyer et al., 2008). Furthermore, JMJD1a expression 
was also shown to be hypoxia regulated in vivo, through hypoxia incubation of rats 
(Wellmann et al., 2008). The authors could show, increased JMJD1a mRNA 
expression in hypoxia, in brain, heart, lung, testis, and kidney.  
 
DNA methylation which is strongly associated with heterochromatin formation, i.e., 
closed non transcriptionally active chromatin, has also been shown to be affected by 
hypoxia (Shahrzad et al., 2007). The authors used cancer cell line models, and tumor 
xenografts, to correlate the level of DNA methylation to tumor hypoxia. They could 
observe a hypomethylated phenotype in tumor xenografts studies, by correlating 
hypoxyprobe staining to DNA methylation staining in xenografted tumors in SCID 
mice (Shahrzad et al., 2007).  
 
Finally the chromatin remodeling factors mating type switching sucrose non-
fermenting (SWI/SNF) complexes have also been shown to be important for HIF-1α 
transactivation activity (Kenneth et al., 2009). Through overexpression of SWI/SNF 
subunit proteins, BRG1, BAF170 and BAF57, HRE luciferase activity was increased 
in hypoxia incubated U2OS cells, suggesting how SWI/SNF complexes potentiate 
the hypoxia response. Furthermore, by siRNA depletion of the aforementioned 
subunits in U2OS cells, hypoxia target gene Glut1 protein levels were abrogated at 
4 hours of hypoxia incubation compared to control (Kenneth et al., 2009). Indicating 
that HIF-1α transactivation requires some chromatin remodeling to occur, at hypoxia 
target genes.  
 
Epigenetic regulation of components in the HIFα pathway has been shown, in a 
study of human patients with multiple myeloma, 33% of patients had increased DNA 
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methylation in the VHL locus (Hatzimichael et al., 2009), functionally decreasing the 
overall levels of pVHL leading to uncontrolled HIF-1α stability, which was correlated 
to a more severe outcome. Another study focusing on DNA methylation showed how 
EGLN3 (PHD3) locus was hypermethylated in B-cell lymphomas and multiple 
myelomas (Hatzimichael et al., 2010), correlating yet again to a more unfavorable 
outcome. DNA methylation enzyme DNMT3a has also been implicated in the 
regulation of EPAS1 gene transcription. By comparing non-transformed and tumor 
cell lines, the authors could show how EPAS1 mRNA and protein was regulated in 
the presence of DNMT3a (Lachance et al., 2014), furthermore by performing short 
hairpin RNA (shRNA) knockdown targeting DNMT3a, cells would reactivate the 
expression and protein accumulation of EPAS1, leading to increased hypoxic cell 
survival and increased tumor size xenografts.  
 
A more recent study has elucidated the aspects of epigenetic regulation and HIFα 
binding, with the chromosome conformation capture (3C) technique, (Platt et al., 
2016), could show HIFα DNA binding sites are established even in physiological 
oxygen tension. By using the 3C technique, coupled to ChIP-seq data of HIFα 
binding, to both proximal and distal sites in the MCF-7 cell genome, the authors could 
show RNA-polymerase II (RNAPII) occupancy was already present at these HIFα 
sites and distal enhancers, even under physiological oxygen conditions. The release 
and activation of RNAPII, during hypoxia is therefore correlated to hypoxia target 
gene expression, observed solely during hypoxia incubation of MCF-7 cells. Which 
suggests that not all HIFα binding sites are established during hypoxic conditions, 
furthermore, this might explain the rapid mRNA expression profiles seen in short 
term hypoxia exposures.  
 
1.2.1 The effect of low oxygen tension in tumors 
 
Cancer, the disease of uncontrolled cell proliferation. Is the second leading cause of 
mortality in the United States although estimated new cancer cases are projected to 
be higher in females then males, the estimated deaths are projected to be higher in 
males (Siegel, Miller and Jemal, 2018).  
 
As with all cells, O2 is a vital component of their sustainable survival, the organisms 
blood vessels are fine tuned to deliver the proper amount of oxygen throughout the 
entire lifespan. When cells initiate uncontrolled cell proliferation, the limits of oxygen 
diffusion from nearby blood vessels will eventually lead to hypoxic cells, which in turn 
stabilize HIFα, concomitantly induce gene expression of target genes involved in 
angiogenesis, the process of sprouting new blood vessels from pre-existing ones 
(Rey and Semenza, 2010). HIF-1α induces expression of VEGFA which in turn 
initiates the signal transduction cascade by binding to VEGFR2, a receptor tyrosine 
kinase pivotal for angiogenesis located on the surface of endothelial cells, pericytes 
and vascular smooth muscle cells (Rey and Semenza, 2010).  
 
Through successive cell cycle progressions, cancer cells will acquire somatic 
mutations, the mutation load seems to be cell type specific, for example breast and 
ovarian cancers have a high mutation rate in the breast cancer type 1 (BRCA1) gene, 
which has been shown to be epigenetically regulated via hypoxia (Lu et al., 2011). 
Through ChIP-qPCR analysis, the authors could show how the BRCA1 and RAD51 
locus in MCF-7 cells, acquired H3K9me2/3 modifications during hypoxia, with 
decreases in H3K4 methylation. Furthermore, acetylation of H3K9 was decreased 
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during hypoxia at these loci, which could be reversed upon HDAC inhibitor treatment 
with TSA. Finally, the authors could show that lysine specific histone demethylase 1 
(LSD1), is one of the factors, that mediates the loss of H3K4 methylation during 
hypoxia in MCF-7 cells (Lu et al., 2011), through shRNA stable transfection of MCF-
7 cells with LSD1 specific shRNA constructs. Demonstrating how hypoxia dependent 
epigenetic effects, can influence genetic stability through inhibition of BRCA1 and 
RAD51 gene loci.  
 
Approximately 50-75 % of renal clear cell carcinomas (RCCs) have inactivating 
mutations in the tumor suppressor gene VHL (Banks et al., 2006). Generating 
increased HIFα stabilization irrespective of O2 tension (Shen and Kaelin, 2013). HIFα 
overexpression in RCC has been shown to have isoform specific effects, HIF-1α 
seems to act as a tumor suppressor, located on chromosome 14q frequently deleted 
in RCC tumors (Shen et al., 2011), whereas HIF-2α seems to be necessary and 
sufficient for RCC mouse xenograft engraftment (Shen and Kaelin, 2013).  
 
As previously mentioned, HIFα proteins have been shown to modulate several 
epigenetic writers, erasers and readers, it is therefore not improbable to assume that 
hypoxic tumors will exhibit deregulated epigenetic effects. Several solid tumors have 
been shown to have hypoxic cores with strong HIFα staining, like the palisading 
necrotic cells of glioblastoma tumor biopsies (Schito and Semenza, 2016). For 
instance, in human tubular epithelial cells, HIF-1α was shown to induce the 
expression of Polycomb Group RING Finger Protein 4 (BMI1), a key component of 
the Polycomb complex 1 (PRC1) epigenetic modifier (Du et al., 2014). Enhancing 
the epithelial to mesenchymal (EMT) transition, which is associated to increased 
metastasis. HIF-1α was also shown to regulate SNAIL1 in Hepatocellular carcinoma 
cells (Zhang et al., 2013), another EMT related marker. Lastly, using several cancer 
cell lines and in vivo models, (Wu et al., 2011), could show how hypoxia drives 
HDAC3 expression, in turn mediating WDR5 dependent histone methylation on 
H3K4, upregulating mesenchymal gene programs contributing to EMT transitions. 
Hypoxia and the HIFα proteins modulate the epigenome through various 
mechanisms, potentiating cancer progression in a cell type dependent manner.  
 
Intratumoral hypoxia has been associated with many of the steps in tumor 
progression, interaction between the tumor microenvironment (TME) and 
surrounding tissues, has been shown to play a major role in tumor progression. 
Stromal cells that are part of the TME have been shown to promote metastasis 
through a variety of mechanisms (Hanahan and Coussens, 2012; Qiu et al., 2017). 
The TME is composed of several cell types, tumor associated macrophages (TAMs), 
cancer associated fibroblast (CAFs), cells of the innate immune system like 
macrophages as well as NK cells, and the adaptive immune system CD8+ T-
lymphocytes (Rankin, Nam and Giaccia, 2016). In a recent study performed on 
human patients with metastatic melanoma (Hugo et al., 2016), administration of anti-
programmed cell death 1 (PD-1) antibodies were delivered to these patients which 
acts as a checkpoint blockade regime increasing the potential survival of T-cells. 
Whole exome sequencing of the patient’s tumors revealed a transcriptomic signature 
which evaded immune surveillance and the anti-PD-1 regime, furthermore, the 
transcriptome was closely related to mesenchymal transition, hypoxia, wound 
healing and angiogenesis (Hugo et al., 2016), linking hypoxia signatures to immune 
evasion.  
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1.2.2 T-cell activation and the epigenetic control of cell fate 
 
Immune cells, such as B-cells and T-cells are born in the bone marrow, through 
successive differentiation of the hematopoietic stem cell. T-lymphocytes migrate out 
from the bone marrow, subsequently ending up in the Thymus, a small organ 
responsible for the correct environment for T-cell differentiation. T-lymphocytes in 
the Thymus will undergo positive and negative selection, ensuring proper function of 
the cells and either express the surface marker CD4+ or CD8+. After which they will 
migrate out from the Thymus and depending on the chemokine receptors they 
express, either continue circulating in the blood or migrate to the lymph nodes or 
other organs.  
 
T-lymphocytes express the T-cell receptor (TCR), which is composed of variable α 
and β chains, upon encounter with antigen presenting cells (APCs) which display the 
antigen (Ag) through major histocompatibility complex class I (MHC I in mice and 
HLA in humans), CD8+ T-lymphocytes will activate the TCR upon Ag recognition 
which engages complementary receptor CD3 and CD28 (Van Der Merwe and 
Dushek, 2011) initiating a complex phosphorylation cascade dependent on Akt, 
mammalian target of rapamycin complex I and II (mTORC I/II), and LcK  (Smith-
Garvin and Koretzky, 2009). Subsequently leading to gene expression programs that 
will expand the CD8+ T-cells, increase their size, change their metabolism and 
differentiate towards specific cell fates (Chisolm and Weinmann, 2015).  
 
A naïve CD8+ T-cell has not yet encountered any foreign antigen while outside the 
thymus, during which it primarily uses fatty acid synthesis for energy production 
(Pearce et al., 2009). However during TCR triggering, a rapid metabolic shift takes 
place, which induces glycolytic genes and metabolic output towards glycolysis (van 
der Windt and Pearce, 2012). mTORC1 and pyruvate dehydrogenase kinase 1 
(PDK1) have been shown to be part of this regulation, shifting to a more glycolytic 
metabolism. HIF-1α has been shown to be induced during CD3 mediated ex vivo 
TCR triggering from human PBMCs (Nakamura et al., 2005), as stated previously, 
HIF-1α is known to regulate several glycolytic genes, it is not entirely improbable to 
assume a role for HIF-1α in changing the metabolic phenotype of CD8+ T-cells after 
activation. This assertion is suggested from the observation of the sibling cells CD4+ 
T-cells, were HIF-1α has been implicated in the glycolytic shift from naïve to TH17 
and Treg cells (Dang et al., 2011; Shi et al., 2011).  As we could see in Paper II, HIF-
1α knockout CD8+ T-cells, displayed improper activation, compared to wild type 
littermates, these effects, had functional consequences. For instance, in increased 
tumor volume and growth in several tumor xenograft models. The cell intrinsic effects 
of loss of HIF-1α in CD8+ cells during tumor progression is still not clear. Further 
studies will be needed.  
 
After the initial TCR trigger, naïve CD8+ T-cells will differentiate towards one of 
several cell types, effector (EFF), stem cell effector (SEM), central memory (CM) and 
effector memory (EM) (Henning, Roychoudhuri and Restifo, 2018). Two models 
have been proposed which differ slightly in their mode of action. The linear model 
stipulates that the strength of the antigen signal drives the CD8+ T-cells to TCM 
(Opferman, Ober and Ashton-Rickardt, 1999). TCM cells have the capacity to recall 
antigen response in adoptive transfer experiments in antigen-free recipient mice 10 
weeks post initial infection (Opferman, Ober and Ashton-Rickardt, 1999). This model 
places the TCM as an intermediate cell type in the differentiation cascade, further 
evidence for the placement of TCM as an intermediate in the linear model, comes 
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from transcriptional analysis of CD8+ T-cell clones, were TCM cells are similar in the 
transcriptional readouts of naïve cells as well as TEFF cells (Holmes et al., 2005; 
Roychoudhuri et al., 2015).  
 
The circular model of T-cell differentiation proposes that a proportion of T-cells 
differentiate from naïve cells to effector cells and finally to memory cells. Secondary 
antigen encounter is intercepted by TEM, restarting the cycle anew with 
dedifferentiation and redifferentiation occurring throughout the different states 
(Akondy et al., 2017; Youngblood et al., 2017). These effects have been proposed 
to occur both transcriptionally and epigenetically (Henning, Roychoudhuri and 
Restifo, 2018). 
 
The histone PTM H3K9me3 is catalyzed by suppressor of variegation 3-9 homolog 
1 (Suv39h1), one of many histone methyltransferases which can perform this 
reaction.  Through CD8+  T-cell specific KO of Suv39h1, (Pace et al., 2018) could 
show how stem cell genes are deregulated in the KO animals compared to wild type 
littermates through single cell RNA sequencing technology. After Listeria 
monocytogenesis infection in mice, Suv39h1 was important for peripheral effector 
differentiation versus memory T-cell differentiation. Therefore Suv39h1 seems to be 
important for the commitment of CD8+ T-cells to memory cell differentiation (Pace et 
al., 2018).   
 
One important effector molecule which is expressed by CD8+ T-cells, is the 
granzyme family, granzyme B (GzmB) expression is associated with cytolytic activity 
and is usually expressed in high amounts in terminally cytolytic T-lymphocytes 
(CTLs). Epigenetic regulation of the GzmB locus has been shown to occur in CD8+ 
T-cells through acetylation of lysine 9, H3K9Ac. (Araki et al., 2008) could show 
increased H3K9Ac levels in the GzmB locus in memory T-cells compared to naïve, 
which correlated to increased mRNA levels, conversely, decreased acetylation of 
H3K9Ac in the GzmB locus via HAT inhibition with curcumin, was associated with 
less GzmB expression (Araki et al., 2008). This suggests that memory T-cells can 
rapidly switch on the expression of CTL effector molecules, through epigenetic 
mechanisms.  
 
H3K4me3 and H3K27me3 are two opposing histone PTMs, H3K4me3 is strongly 
associated with expression of a genetic loci, however H3K27me3 is strongly 
associated with heterochromatin. Crompton J et. al generated global H3K4me3 and 
H3K27me3 ChIP-seq maps of CD8+ T-cells during differentiation (Crompton et al., 
2016). The authors showed how the levels of H3K4me3 were changed between the 
different T-cell subtypes, for instance, H3K4me3 levels were high in the promoter of 
transcription factor 7 (Tcf7) in naïve cells and TSCM subtypes, however the TCM and 
TEM subtypes progressively lost this modification. These data suggest as with the 
previous H3K9Ac data (Araki et al., 2008), epigenetic modifiers such as 
methyltransferases and demethylases are important for the acquisition of cell fate 
during T-cell differentiation. As we could show in Paper III, exogenous administration 
of S-2HG during TCR activation for 3 days, showed global histone acetylation 
decreases, furthermore, ChIP-qPCR analysis of target gene promoters showed 
differential acetylation enrichment between vehicle and S-2HG treated CD8+ T-cells, 
possibly linking H3K9Ac loss at target gene promoters to cell type differentiation.  
During cell type differentiation from naïve to effector cell, CD8+ T-cells have been 
shown to have differential methylation regions (DMRs) (Scharer et al., 2013). During 
lymphocytic choriomeningitis virus (LCMV) infection in mice, antigen specific naïve 
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cells were compared to 8-day long effector CD8 cells, promoter DMRs were 
characterized between the naïve and effector cells. Unexpectedly, DMRs were 
negatively correlated to gene expression, having increased DNA methylation at 
naïve associated genes in effector cells. DNA methylation is thus one possible 
mechanism of cell type determination in T-cells. Altogether, many epigenetic 
mechanisms could impact the differentiation from naïve to effector CD8+ T-cell, with 
multiple mechanisms acting in conjunction with one another, generating a complex 
image of probable outcomes.   
1.2.3 R/S-2-Hydroxyglutaric acid production and its epigenetic effects 
 
The Krebs cycle proposed by Adolf Krebs in the late 1930s, is the primary metabolic 
pathway during aerobic processes in cells and tissues. Generation of energy in the 
form of ATP as well as numerous co-factors for enzymes and the oxidation of 
carbohydrates, proteins and lipids (Akram, 2014) and illustrated in Fig.3. The 
isocitrate dehydrogenase enzymes 1 and 2 (IDH1/2) convert isocitrate to 2-
oxoglutarate (α-ketoglutarate) which is further metabolized to succinyl-CoA by α-
ketoglutarate dehydrogenase (Akram, 2014). Mutations in the TCA cycle were often 
thought of as detrimental to cells, however (Dang et al., 2009), showed how a single 
point mutation in IDH1 (R132H) shifted the enzyme output towards generating R-2-
Hydroxyglutaric acid (R-2HG). The study found that in 80% of grade II-III gliomas 
and secondary glioblastomas IDH1 R132H mutation was present, defining R-2HG 
as an oncogenic metabolite (Dang et al., 2009). Following this study, (Figueroa et 
al., 2010), showed how IDH1/2 mutations in human acute myeloid leukemia (AML) 
patient cohort had mutually exclusive mutations of either IDH1/2 or ten-elven 
translocation 2 or tet methylcytosine dioxygenase 2 (TET2), generating a DNA 
hypermethylation phenotype in these cancers. The TET family of enzymes 
composes 3 known members to date, TET1, TET2 and TET3, all have been shown 
to perform DNA demethylation reactions involving TDG DNA repair and successive 
oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Tahiliani et al., 2009; He et al., 
2011; Ito et al., 2011). The consequences of IDH1/2 mutation were soon to be 
unraveled, as predicted by Dang in 2009, (Chowdhury et al., 2011) showed how R-
2HG inhibited histone lysine demethylases from the jmjC domain containing histone 
demethylase family (JMJD2A). Koivunen P et.al showed how R-2HG and not S-2HG 
stimulated PHD1/2 activity in astrocytes, virally transfected with R132H IDH1, 
successfully diminishing HIF-1α and HIF-2α protein levels (Koivunen et al., 2012). 
DNA repair enzymes were also shown to be sensitive to R-2HG overproduction 
(Wang et al., 2015). The authors showed using established glioblastoma cell lines 
U87-MG and U373-MG stably expressing the IDH mutation R132H, increased DNA 
damage which was attributed to the inhibitory effects of R-2HG on alpha-
ketoglutarate-dependent dioxygenase alkB homologs 2/3 (ALKBH2/3). Rendering 
the IDH1 mutated cancer cells sensitive to alkylating chemotherapy.  
 
Recently, two papers were exploring the hypoxic response to 2HG accumulation in 
various cell types, (Intlekofer et al., 2015) illustrated how hypoxia incubation of 
SF188 glioblastoma cell line, accumulated S-2HG in millimolar concentrations. 
Furthermore, the S-2HG levels were generated in these cells through malate 
dehydrogenase 1 and 2 (MHD1/2). Through siRNA transient knockdown strategies 
of MHD1 and 2, total levels of S-2HG could be shown to decrease in hypoxia. 
Similarly, (Oldham et al., 2015) could show MHD1 and 2 dependence in generating 
S-2HG during hypoxia, however instead of using cancer cell lines, primary mouse 
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lung fibroblasts were used. Both of these papers suggested that HIF-1α was not 
necessary for the induction of S-2HG during hypoxia, although they could see 
decreases in the overall 2HG pool in siRNA knockdown experiments targeting HIF-
1α. Furthermore, these papers incubated the cells in 0.5 % and 0.2 % oxygen tension 
respectively, these very low almost anoxic conditions could have effects on the redox 
balance in these cells. These studies beautifully explored the probability of a HIF-1α 
driven 2HG effect, however in their model systems HIFα was not necessary. Tyrakis 
P et.al (Tyrakis et al., 2016) highlighted the necessity of hypoxic HIF-1α driven S-
2HG and R-2HG production in mouse primary CD8+ T-cells. Using the power of 
knockout mice models, Tyrakis P et.al could show that VHL-/- negative CD8+ T-cells 
produced the highest amount of 2HG and the dominant enantiomer was S-2HG. The 
accumulated hypoxic S-2HG was lost in the HIF1a-/- CD8+ T-cells, however the HIF-
2a-/- CD8+ T-cells had no effect on the 2HG pool. S-2HG was shown to accumulate 
in CD8+ T-cells during activation which peaked between days 2 and 4, suggesting 
that S-2HG had some endogenous effects. Exploring the possibility of S-2HG 
affecting T-cells, the authors characterized both the phenotypic markers of activation 
and differentiation, showing when treating T-cells exogenously with a cell permeable 
S-2HG dose, effector cytokines as well as proliferation was reduced, suggesting that 
S-2HG is skewing T-cells towards a more memory like phenotype. In adoptive 
transfer experiments, the authors could show robust recall effects of S-2HG treated 
CD8+ T-cells. In tumor xenograft models, pre-treated OT-1 CD8+ controlled tumor 
growth in vivo more successfully compared to vehicle treated. Thus, it appears that 
hypoxia stabilized HIF-1α drives S-2HG accumulation in T-lymphocytes, 
furthermore, promotes a higher proportion of memory T-cells in vivo, potentially 
being of clinical value.  
 
 
Fig 3. TCA cycle schematic. Krebs cycle, or TCA cycle schematic, illustrated here in red, are 
the products in each step of the cycle. In black, the corresponding enzymes responsible for 
the said product. 2-hydroxyglutaric acid (2HG) products, are produced in the steps between 
isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase.  
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2 METHODS 
2.1 CHROMATIN IMMUNOPRECIPITATION (CHIP) 
 
Chromatin immunoprecipitation (ChIP) was first described (Boyd and Farnham, 
1999), many advances have been made to both antibody quality as well as the bead 
quality, which ultimately generate better binding maps. Further advances have been 
made coupling the power of ChIP to other platforms such as microarray and DNA-
sequencing. The first study to couple ChIP to microarray was performed by Lieb.D 
et.al, (Lieb et al., 2001), they studied the Rap1 telomere binding protein, and had a 
striking resolution of 2 kb binding maps. The second revolution was achieved when 
ChIP was coupled to DNA whole genome sequencing, (Barski et al., 2007). These 
studies paved the way for current advances in molecular biology and beyond.  
The current protocol used in Papers I-III are described in detail in the methods 
section, the conceptual methodology is as follows. Living cells are fixed with 
formaldehyde, generating protein-protein as well as DNA-protein cross-links. The 
chromatin is sheared through either sonication or enzyme digestion or both, to 
produce chromatin at variable sizes. Following chromatin shearing, 
immunoprecipitation with specific antibody targeting the fraction of DNA-protein 
crosslinked molecules is performed. Subsequently, protein A or protein A-G beads 
are added, which bind to the DNA-protein-antibody molecules. De-crosslinking of 
formaldehyde linkages frees up the DNA-protein-antibody-beads molecules, which 
are then eluted from this complex to generate the small fragments of DNA which 
should be specific towards the primary antibody used. The DNA is purified and 
compatible for further analysis, such as qPCR, microarray or sequencing.  
2.2 SODIUM DODECYL SULPHATE – POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
 
SDS-PAGE or more commonly referred to as Western blot, was in its current form 
first described by U.K Laemmli in 1970. Western blot technique allows for separation 
of protein size of the lysate, through acrylamide gel electrophoresis. The SDS in the 
solution will linearize and together with a strong reducing agent such as β-
mercaptoethanol, keep the proteins in the primary structure. SDS is also binding the 
linearized protein which produces an overall negative charge of the molecule. This 
together with the acrylamide gel and applied current, separates proteins by size only, 
ensuring that larger proteins are migrating slower and smaller proteins faster. After 
separation has completed, transfer of the proteins to a membrane (either PDFV or 
nitrocellulose) is performed. Subsequently the membrane is blocked with milk or 
commercially available blocking solutions, after blocking, the membrane is incubated 
with primary antibody solution targeting the protein of interest. Another wash step is 
performed and finally secondary antibody targeting the primary IgG isotype. Lastly, 
membrane development and data interpretation.  
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2.3 QUANTITATIVE REVERSE-TRANSCRIPTASE PCR 
 
Polymerase chain reaction (PCR) is a very powerful technique which is widely used 
in many fields, from forensic science to determination of illnesses. The principle of 
PCR is based upon DNA polymerase needing to have a primer sequence to start its 
reaction, therefore, by designing primer sequences for the target genetic region of 
interest, one can determine if the gene is expressed, how much of the gene product 
is present or simply if the gene is present. Primer design is consequently very 
important, there are multiple tools available online for free as well as paid versions, 
that calculate the GC content, specificity and self-alignment characteristics of the 
primer sequences. GC content is an important factor because GC rich regions are 
notoriously harder to amplify and self-alignment of the primer pairs is also important 
which generates primer dimers which in turn lowers the specificity.  
 Quantitative reverse transcriptase PCR is performed by extracting the mRNA of the 
target cell or organ, performing complementary DNA (cDNA) synthesis and 
measuring the amount of mRNA present in the elute with a PCR reaction. The 
determination of mRNA is put into relation to a housekeeping gene which is known 
not to change its expression in the actual experiment, and the data is represented 
as fold change over housekeeping gene expression.  
2.4 MICROCOCCAL NUCLEASE (MNASE) PROTECTION ASSAY 
 
Micrococcal nuclease (MNase) enzyme digests non-histone bound DNA. MNase has 
been widely used to map enhancer regions, promoter regions and other active sites 
in the genome. The MNase protection assay is used to map HIFα responsive gene 
promoter auxiliary factor remodeling. Nuclear extracts from normoxia and hypoxia 
treated cells are either undigested or subjected to 15 minutes of MNase digestion in 
37° C and stopped by adding SDS and EDTA solution for 5 minutes. The DNA is 
purified and RT-qPCR is performed. The data is then analyzed and represented as 
% protection of digestion, using the qPCR data from the undigested values and 
calculating using the undigested values as threshold.   
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3 AIMS 
 
The aim of the research presented in this thesis, was to acquire a more in depth 
understanding of HIFα dependent processes, such as hypoxic epigenetic effects as 
well as, cell intrinsic effects of loss of HIFα.  
• The role of hypoxia in cell epigenetic effects, in cancer cell models 
• The loss of HIFα during CD8+ cell proliferation and function 
• HIF-1α downstream effects, such as accumulation of S-2HG, and its instrinsic 
effect on CD8+ T-lymphocytes 
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4 RESULTS  
 
4.1 PAPER I  
 
It is has been widely observed that tumor hypoxia is an important hallmark of cancer 
progression (Nobre et al., 2018). Although the mechanism(s) vary depending on cell 
of origin, hypoxia exerts its function nonetheless. Most solid tumors will outgrow their 
oxygen diffusion limits, hence slowly and gradually become more hypoxic, which are 
characterized usually with a malformed vasculature. Hypoxia is also not uniformly 
occurring throughout the tumor (Jiang et al., 2012), giving rise to areas which are 
well vascularized, as well as, areas which are highly hypoxic. Overall, a hypoxic 
signature is correlated to lower disease free survival (Vaupel and Mayer, 2007).  
In this present study, we focused our attention to the epigenetic effects of hypoxia, 
and the role HIF-1α during hypoxic insults. Established cancer cell line models, SK-
N-Be(2)c and HepG2, neuroblastoma and hepatoma cancer cells respectively, two 
model cell lines widely used in the field. We incubated the cells at various time points 
of hypoxia and reoxygenation. Cell nuclei were harvested and micrococcal nuclease 
digestion was performed. DNA was purified and qPCR was performed, with primers 
targeting hypoxia regulated gene promoters.  
 
We observed that HIF-1α and HIF-2α proteins were expressed and detectable under 
our hypoxia timepoints. We could see HIF-1α protein accumulation in SK-N-Be(2)c 
cells as early as 4 hours of hypoxia incubation at 1% oxygen, however, HIF-1α 
protein levels were less at later hypoxia time points, 24 and 48 hours respectively, 
with complete degradation of HIF-1α at our reoxygenation timepoints 4 and 24 hours. 
Conversely, HIF-2α protein levels were increased gradually from 4 hours of hypoxia 
and maintained stability until 48 hours of hypoxia. In HepG2 cells, HIF-1α protein 
was stably visible from the early 4 hour timepoint of hypoxia, with strong HIF-1α 
protein band even after 4 hours of reoxygenation. mRNA expression of target genes, 
CA9, PGK1, PFKFB4, GYS1, P4HA2, KDM3A, PDK2, TMEM45A, and BNIP3, 
showed hypoxia dependent increases in mRNA relative to housekeeping gene β-
actin.  
 
We continued the analysis, by performing ChIP-qPCR following hypoxia incubations, 
using HIF-1α and HIF-2α specific antibodies. We could detect HIF-1α and HIF-2α 
protein binding to HRE sequences in CA9, PGK1, PFKFB4, and PDK2 in both cell 
lines. The majority of HIFα protein was bound during our hypoxia incubations, with 
sharp decline in association with the HRE´s at our reoxygenation timepoint of 1 hour 
at 21% oxygen.  
 
We used DNase 1 hypersensitivity and ChIP-qPCR, using antibodies for histone 3 
protein and, histone 3 lysine 9 acetylation. As our DNase-seq illustrates, the peaks 
were concentrated on the transcription start sites (TSS) of CA9, PGK1, PFKFB4, 
GYS1, P4HA2, KDM3A, PDK2, TMEM45A, and BNIP3, with GYS1 and KDM3A, 
having peaks over their respective HRE sequences.  Our histone 3 lysine 9 
acetylation ChIP-qPCR shows hypoxia dependent increases in hypoxia timepoints 4 
and 24 hours at the CA9 HRE/TSS, and PGK1 TSS locus respectively. With 
decreasing amounts of histone 3 lysine 9 acetylation being detected at 
reoxygenation timepoints 4 and 24 hours.  
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We observed chromatin organization differences in target gene promoters of hypoxia 
regulated genes, our micrococcal nuclease coupled to qPCR (MNase) assay allowed 
us to carefully distinguish between two types of chromatin conformations. 
Nucleosome organization differences were divided into inducible NFRs (iNFRs) and 
constitutive NFRs (cNFRs). iNFRs were observed for target genes such as CA9, 
whereas, cNFRs were observed for PGK1, PDK2 and PFKFB4. Our reoxygenation 
time points, 4 and 24 hours post 24 hours of hypoxia, enabled us to observe a pattern 
of reversibility. Through siRNA technology, targeting SIN3A, an adaptor protein 
present in several chromatin remodeling complexes, we could observe a necessity 
for SIN3A in the reestablishment of chromatin structure.  
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4.2 PAPER II  
 
Cytotoxic T-lymphocytes or CTLs, are a major part of the adaptive immune response. 
They infiltrate tumors, clear pathogens, and mediate the cytolytic effects of the T-cell 
lineage. The HIFα transcription factors are upregulated in CTLs during low oxygen 
tensions, as well as, thought to aid CTLs when encountering hypoxic niches. To 
explore the differences between the main two HIFα isoforms role in T-lymphocyte 
biology and function, we employed a conditional knockout technique, using the distal 
lymphocyte protein tyrosine kinase gene (Lck) promoter (dLck) LoxP CRE system. 
Deleting exon2 from Hif1a and Epas alleles, generating ablated HIF-1α and HIF-2α 
proteins in CD8+ T-cells.  
 
Our characterization of the two main HIFα isoforms was initiated in wild type, splenic 
extracted CD8+ T-cells, showing activation and time dependent mRNA expression 
of HIF-1α and HIF-2α relative mRNA compared to unstimulated T-cells. With peak 
levels at 72 hours post ex vivo αCD3ε/αCD28 stimulus. We detect HIF-1α, and HIF-
2α protein levels during our activation time points, with HIF-1α protein stability being 
highest at 24 hours post activation, while, HIF-2α maintains a stable protein level 
throughout our activation time.  
 
Deletion efficiency was almost 100% in the HIF-1αfl/fl dLckCRE and HIF-2αfl/fl dLckCRE 
T-cells, measured through genomic DNA PCR, and protein quantification of nuclear 
extracts.  Proliferation was not affected by either HIFα isoform deletion. However, 
HIF-1α target gene expression of glucose genes, Hk2, Pdk1, Mct4, and Pgk were 
significantly reduced in 1% oxygen, in HIF-1αfl/fl dLckCRE T-cells. Furthermore, 
extracellular flux, lactate, and glucose uptake were impaired in HIF-1αfl/fl dLckCRE 
cells, which were not affected in HIF-2αfl/fl dLckCRE T-cells.  
 
Next, we determined how hypoxia, HIF-1α and HIF-2α impact T-cell effector 
differentiation. Properly activated and differentiated effector CD8+ T-cells 
downregulate CD62L, a chemokine receptor targeting T-cells to secondary lymphoid 
tissues. HIF-1α deficient, not HIF-2α deficient, effector CD8+ T-cells failed to 
downregulate CD62L. Additionally, T-cells lacking HIF-1α, decreased the production 
of effector cytokine interferon gamma (IFNᵧ), and tumor necrosis factor alpha 
(TNFα). However, hypoxia treatment increased the production of granzyme B 
(GzmB) and activation related costimulatory molecules CD137, OX40, and GITR. 
Hypoxia also increased the production of checkpoint receptors PD-1, TIM3, and 
LAG3. The production of these molecules was HIF-1α dependent, and not HIF-2α, 
with HIF-2α deficient T-cells, displaying almost identical levels to wild type 
littermates. Lastly, we observed activation dependent and hypoxia dependent 
VEGF-A production, which was also, HIF-1α dependent. Thus, hypoxia, and HIF-1α, 
increase the production of activation related molecules, and hypoxia target genes, 
such as VEGF-A.  
 
In line with the aforementioned, improper activation phenotype observed in the HIF-
1α deficient T-cells, we sought to identify in vivo specific effects of these 
observations. To this end, we subcutaneously injected Lewis lung carcinoma (LLC), 
and B16-F10, melanoma cells into mice lacking specifically, HIF-1α or HIF-2α in T-
lymphocytes (HIF-1αfl/fl dLckCRE and HIF-2αfl/fl dLckCRE). We compared tumor growth 
to wild type mice, and the corresponding loxP allelic mice (HIF-1αfl/fl and HIF-2αfl/fl). 
HIF-1α deficient T-cells, showed increased tumor volume, and weight, compared to 
HIF-1αfl/fl animals. HIF-2α deficient T-cells, showed similar tumor volume and weight, 
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compared to HIF-2αfl/fl animals. When analyzing the proportion of tumor-infiltrated 
CD8 T-cells to CD4 T-cells, we could observe a skewing in the HIF-1α deficient T-
cells, showing less CD8+ infiltration in the tumors. Correspondingly, lower levels of 
co-stimulatory markers CD137 and GITR, expression was also observed in the 
tumor-infiltrated T-cells, with lower expression of checkpoint receptors PD-1, LAG3, 
and TIM3. The endothelial nature of the subcutaneous tumors, and the notion that 
HIF-1α deficient T-cells have lower tumor-infiltration capacity, we employed an in 
vitro co-culture experiment, with Boyden chamber plates. We cultured early passage 
of pulmonary endothelial cells, with either, HIF-1α deficient T-cells or wild type 
control T-cells, in hypoxic conditions. We observed, approximately 50% less 
migration in HIF-1α deficient T-cells, in hypoxia 1% oxygen, after 24 hours, 
compared to wild type control cells. Lastly, we injected mice with fluorescence-
conjugated tomato lectin, in order to assess tumor vascularization, in mice bearing 
LLC tumor. Mutant T-cell, tumor bearing mice, showed vascular segment length 
differences, and altered vessel straightness compared to wild type mice. The in vivo 
results point therefore, to a pivotal role of intact HIF-1α in CD8+ T-cells, to properly 
control tumor size, weight, and tumor-infiltration.  
 
Immunotherapy, is beginning to emerge as a viable option for certain tumors, in 
clinical settings. We therefore, explored if HIF-1α was necessary for the acquisition 
of effector function. By using the established ovalbumin recognizing TCR receptor 
expressing transgenic mouse, OT-1 mouse. We generated HIF-1α conditional 
knockout OT-1 CD8+ T-cells, with and without dLckCRE expression. CD8+ T-cells 
were then activated by addition of SINFEKL, the cognate TCR ligand in the OT-1 
system. As with previous CD8+ T-cells lacking HIF-1α, the OT-1 HIF-1α knockout T-
cells, were able to proliferate and survive during antigen stimulation, although, 
CD62L downregulation was defective with similar phenotype to non-OT-1 CD8+ T-
cells lacking HIF-1α. OT-1 mutant T-cells, showed altered expression of TNFα, 
GzmB, and IFNᵧ after re-stimulation. We then went on to perform adoptive transfer 
experiments, to assess how HIF-1α deficient OT-1 cells, migrate in vivo. By co-
transferring control CD45.1+ and mutant CD45.1+ TdTomato+ CD8+ T-cells in a 1:1 
ratio, into CD45.2+ host mice, challenged with B16-OVA tumors. Subsequently, 
determining the relative amount of each genotype, migrating to the lymph node, 
spleens, and tumors 48 hours after adoptive transfer. We could observe, that HIF-
1α deficient OT-1 cells, migrated more to the lymph node, with less migration to the 
B16-OVA tumors. OT-1 HIF-1αfl/fl T-cells managed to control tumor growth, 
compared to OT-1 HIF-1α dLckCRE mice, which also manifested as decreased 
survival of the mice. Lastly, we used a colon cancer cell line, MC38, which we 
injected into HIF-1 dLckCRE and HIF-1αfl/f mice and subjected them to combinatorial 
antibody-based immunotherapy by administering αCTLA4 and αPD-1 antibodies. 
HIF-1 dLckCRE mice tumors grew larger, compared to HIF-1αfl/f mice. The 
combinatorial therapy controlled the tumor volume in HIF-1αfl/f animals.  
 
Our findings showed altered tumor vascularization in HIF-1α dLckCRE mice bearing 
LLC tumors, which, had lower levels of VEGF-A expression. We sought to gain 
further insight into the role VEGF-A plays in tumorigenesis, expressed from the T-
lymphocyte lineage. We generated VEGFfl/fl dLckCRE CD8+ T-cells, as well as OT-1 
VEGF-A deficient T-cells. The VEGFfl/fl dLckCRE CD8+ T-cells were cultured in 21% 
oxygen and 1% oxygen respectively, to assess if VEGF-A affects T-cells more 
generally. The mutant T-cells were responding in similar fashion in regards to, 
survival, glycolytic metabolism, and expression of cytolytic and 
costimulatory/checkpoint receptors relative to wild type counterpart cells.  OT-1 
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VEGF-A deficient T-cells, expressed similar levels of CD62L, and CD44, as their wild 
type counterpart. However, with a small reduction in expression of costimulatory 
molecules, which did not impact the OT-1 VEGF-A deficient T-cells in an in vitro 
tumor killing assay, in which tumor cells expressed ovalbumin, their cognate TCR 
recognition motif. We adoptively transferred OT-1 VEGFfl/fl dLckCRE or wildtype OT-
1 T-cells, to mice harboring B16-OVA tumors, the resulting tumor volume was not 
significantly changed between wildtype and VEGFfl/fl dLckCRE OT-1 cells, 
consequently, the survival of the mice was overlapping. We injected LLC 
subcutaneously into VEGFfl/fl dLckCRE mice, VEGFfl/fl mice, and wildtype C57/BL6. 
The growth of the tumors, were similar for VEGFfl/fl and wildtype animals, however, 
VEGFfl/fl dLckCRE tumor bearing mice, had an increase tumor volume and weight. 
Analysis of the tumor-infiltrated lymphocytes, illustrated less CD8+ T-cell migration 
into the LLC tumors, in VEGFfl/fl dLckCRE mice. Similar results were obtained with 
HIF-1α deficient T-cells, in regards to infiltration capabilities, however, PD-1 
expression was not affected in the VEGF-A deficient T-cells, as was in the HIF-1α 
deficient T-cells. The VEGFfl/fl dLckCRE mice LLC tumors, showed some signs of 
vessel normalization, which included, increased perfusion, segment length, and 
decreased vessel stiffness. Interestingly, we observed less hypoxia in these tumors, 
by Piminidazole staining, coupled with less Vegfa mRNA from tumor lysates. With 
the signs of normalization of vasculature, we observed in the VEGFfl/fl dLckCRE mice 
harboring tumors, we administered 3 doses of cyclophosphamide and vehicle control 
to VEGFfl/fl dLckCRE mice and VEGFfl/fl mice harboring LLC tumors. Vehicle control 
tumors displayed similar pattern as VEGFfl/fl dLckCRE mice having larger tumors, 
compared to VEGFfl/fl mice, however, the cyclophosphamide group, showed smaller 
tumors in the VEGFfl/fl dLckCRE mice. Lastly, to test the role of VEGF-A in 
spontaneous models of breast cancer, we used the MMTV-PyMT model of 
spontaneous adenocarcinomas, backcrossed to our VEGFfl/fl and VEGFfl/fl dLckCRE 
mice. We did not observe any difference in tumor latency, however, at 17 weeks 
past, tumor weight is significantly increased in VEGFfl/fl dLckCRE mice compared to 
VEGFfl/fl mice. With a more advanced tumor form acquired in the VEGFfl/fl dLckCRE 
mice, scored histologically.  
 
Finally, considering the striking observations in CD8+ T-cell effector differentiation 
loss, and costimulatory/checkpoint dysregulation, in HIF-1α deficient T-cells, we 
sought to understand if HIF-1α was directly binding to CD8+ genes which are 
important for these functions. To this end, we performed ChIP-qPCR analysis on 
wildtype mice, with HIF-1α specific antibody, on CD8+ T-cells cultured at 4 and 24 
hours of 1% oxygen, with corresponding 21% oxygen control. As can be seen in 
Paper II Figure 1, HIF-1α was able to bind mAldoA and PFKB4 canonical target 
genes during hypoxia 1% oxygen, however Lag3, PD-1, CTLA4, and GzmB were 
not bound by HIF-1α at the putative HREs.  
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Paper II Figure 1. ChIP-qPCR analysis in CD8+ T-lymphocytes. (A) ChIP-qPCR analysis of 
putative target gene promoters containing at least one HRE sequence. Cells were incubated 
at (0) normoxia, (4) 4h of hypoxia and (24) 24 hours of hypoxia. mAldoA and PFKFB4 were 
used as positive control. (B) ChIP-qPCR analysis at the 4-hour, 1% oxygen timepoint. n=3 
mice.  
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4.3 PAPER III (MANUSCRIPT) 
 
When treating CD8+ T-cells, exogenously with S-2HG (300µM) for 3 days, numerous 
phenotypical observations can be made. Cell size, as well as cell number are 
affected by this treatment, compared to vehicle (H20) treated cells. The cell 
proliferation effects of S-2HG, during 3-day activation, are seemingly striking, S-2HG 
seems to inhibit cell proliferation with a total amount of cells, after 3-day activation 
being almost 50% less then vehicle treated cells. We know from previous findings 
that, 2-Hydroxyglutaric acids, both R and S enantiomers, will competitively bind to 2-
oxoglutarate dependent enzymes. We therefore, focused our search for epigenetic 
differences, between vehicle, and S-2HG treated CD8+ T-cells. After 3-days of 
activation, T-cells were harvested for histone proteins, naïve cells were harvested 
day 0. Through SDS-PAGE analysis, of histone extracted CD8+ T-cell lysates, we 
could observe a striking acetylation decrease in the S-2HG treated cells. The relative 
amount of H3K9Ac, observed between naïve cells, vehicle treated activated cells, 
and S-2HG, activated cells, was highest in the vehicle activated group. This lead us 
to test if, H3K27Ac, was equally affected by S-2HG. To this end, we performed SDS-
PAGE analysis on the three aforementioned groups, with H3K27Ac antibody. 
Although the vehicle activated group was highest in the signal of H3K27Ac, these 
experiments were not as consistent as with the H3K9Ac antibody. We used several 
approaches, in order to recapitulate the observed effects of S-2HG on H3K9/27Ac. 
With readily available histone acetyltransferase inhibitors, we treated CD8+ T-cells 
with p300 inhibitor Bix as well as Gcn5 inhibitor CPTH2. Bix treatment proved to be 
toxic for T-cells, irrespective of concentration used, however, CPTH2 was well 
tolerated, with a final concentration of 20µM administered during 3-day activation. 
Our SDS-PAGE analysis, of CPTH2, S-2HG and vehicle treated cells, with H3K9Ac 
antibody, showed that S-2HG treatment, yet again, had lowest amount of H3K9Ac, 
CPTH2 HAT inhibitor, could not recapitulate the observed effects of S-2HG alone 
and had no effects on H3K27Ac levels.  
 
Histone acetylation is enzymatically driven, as well, the removal of lysine-
acetylations, with HDAC enzymes. We treated our cells with TSA (3nM), an HDAC 
inhibitor, with and without S-2HG, as well as vehicle treated group. The subsequent 
SDS-PAGE analysis, demonstrated potent H3K9Ac level increases in the TSA 
treated group, however, TSA in combination with S-2HG, showed similar H3K9Ac 
as vehicle treated group. Possibly linking deacetylation as a potential mechanism for 
how S-2HG lowers H3K9Ac in T-cells.  
 
We continued our focus on H3K9Ac, by performing ChIP-qPCR and ChIP-seq 
analysis. The ChIP-qPCR analysis, demonstrated how several genes, showed 
differential H3K9Ac levels during 3-day activation in the presence of S-2HG, 
compared to vehicle and naïve cells. Genes such as, CD44, PD-1 and CD127 
showed differential H3K9Ac levels, in their proximal promoters, having highest 
enrichment in vehicle treated cells. Naïve and S-2HG treated cells, had comparable 
amounts of H3K9Ac in their promoters, albeit, with naïve cells showing slightly more 
enrichment of H3K9Ac. Other genes tested, such as Eomes, TCF7 and IL-2, showed 
no difference in promoter H3K9Ac between the three groups, in our ChIP-qPCR 
analysis. Our ChIP-seq analysis, was performed by Bioinformatics and Expression 
Analysis (BEA) core facility, at KI campus Huddinge. Our ChIP-seq analysis, 
demonstrates how vehicle activated cells, compared to S-2HG treated cells, have 
globally higher levels of H3K9Ac, across the genome. The peak density plots, show 
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how the distribution of peaks are similar between the two groups, with increases in 
H3K9Ac roughly 2Kb upstream of the transcription start sites (TSS), with the highest 
observed peaks being in the gene bodies.  
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5 DISCUSSION 
5.1 PAPER I 
 
Our study highlights some important features of stress inducible gene transcription. 
Severe hypoxia (1% O2), is one of the many ways cells can experience stress. During 
hypoxia, HIFα protein stabilization occurs, with concomitant gene up-regulation. 
However, our focus was on promoter regions of HIFα target genes. Many 
transcription factors require the nucleosomes to be removed or displaced upon cis-
regulation, HIFα proteins are necessary for the remodeling to occur at iNRFs in 
hypoxia regulated gene promoters. Thus, in our study hypoxia acts as a stress 
inducible model system, and the corresponding epigenetic effects observed herein, 
are likely to be applicable to similar models.  
 
The important observation of reversibility, mediated through SIN3A protein, adds 
elegance to the model presented forth. HIF-1α binds to target gene promoters, 
remodels the chromatin, and induces gene transcription. Through recruitment of 
SIN3A and its corresponding complex, either HDACs or NuRD, (McDonel, Costello 
and Hendrich, 2009; Clark et al., 2015), manages to mediate the reestablishment. 
This elegant mechanism of requiring HIF-1α for the initiation of remodeling and 
transcription, with the necessity of SIN3A and corresponding complexes for 
restoration of the chromatin landscape, enables versatility, and co-dependence of 
multiple pathways for proper chromatin management.  
 
Lastly, cell differentiation is linked to the inherent epigenetic state of each cell. One 
way of rationalizing this phenomenon, is to assume that the epigenetic states are 
“fixed” in differentiated cells. However, through the pioneering work of Yamanaka 
and colleagues, we now know, that epigenetic states can be reversed, albeit, through 
overexpression of specific “Yamanaka” factors. The reversibility of cell types in 
normal physiology, is likely to be low, notwithstanding, stem cell niches in the gut 
and the hematopoietic system. Cell type specific epigenetic effects can be observed, 
for instance, nucleosome positioning in an enhancer element of the CSF2 gene, 
which is expressed in mast cells and T-lymphocytes, was shown to recruit specific 
transcription factors in different cell types (Bert et al., 2007). In undifferentiated T-
cells, the enhancer element was induced by NFAT/AP-1 transcription factor 
complexes, that displaced nucleosomes downstream of the TSS. In myeloid cells, 
the enhancer was remodeled by the GATA-1 transcription factor, however, GATA-1 
remodeled nucleosomes which were located upstream of the TSS of CSF2 gene 
(Bert et al., 2007). This illustrates how, conserved genetic elements such as 
enhancers, can be utilized between different cell types for their specific needs.  
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5.2 PAPER II 
 
To better understand and combat, tumor progression, we need to characterize the 
interactions that occur between the different cell types within a given tumor. This will 
ultimately lead to better cancer therapies, and better patient overall survival. 
Although many cell types have been shown to express HIF-1α, the role of HIFα in T-
lymphocyte differentiation and activation, was lacking. We therefore tried to examine 
the role of each HIF isoform in T-lymphocyte biology. We show that CD8+ T-cells 
express both of the HIFα transcripts and proteins after αCD3ε/αCD28 ex vivo TCR 
activation. Furthermore, we observe HIFα target gene up-regulation, such as VEGF-
A, which had the capability to modulate tumorigenesis. Our previous findings 
(Doedens et al., 2013) examined the consequences of loss of VHL in T-cells. With 
increased HIF-1α expression driving effector differentiation phenotype accompanied 
with enhanced viral clearance, with an exacerbated immune response (Doedens et 
al., 2013). Other components in the HIFα pathway have been deleted in T-
lymphocytes, such as the PHD enzymes, responsible for hydroxylation and 
degradation of the HIFs (Clever et al., 2016). The authors used CD4CRE to ablate the 
three PHD proteins in CD4, CD8, and NKT T cells, generating triple KO T-
lymphocytes. They observed increased IFNᵧ expression from the CD8+ T-cells, 
accompanying increased frequency of effector CD8+ T-cell differentiation (Clever et 
al., 2016), which reflects our findings, in which HIF-1α is important for effector 
differentiation of CD8+ T-cells. 
 
The effector differentiation state of CD8+ T-cells is accompanied by a glycolytic 
switch, generating ATP from oxidative and fatty acid metabolism, to glycolysis being 
the predominant form of energy production (Pearce et al., 2009). Our HIF-1α 
deficient T-cells, are impaired in extracellular flux, lactate, and glucose uptake in 
hypoxia conditions, with enzymes such as Hk2 and PDK1 being significantly reduced 
at hypoxia 1% oxygen. Glucose metabolism has been shown to be an important 
mediator and signaling mechanism for CD8+ T-cells (Chang et al., 2013), were the 
authors showed how GAPDH, generated in part through glycolysis, is necessary for 
IFNᵧ production in T-cells. Our HIF-1α deficient T-cells showed reduced expression 
of IFNᵧ during 1% hypoxia. Furthermore, we show loss of HIF-1α, but not HIF-2α, 
results in reduced expression of several cytolytic, and costimulatory molecules 
during hypoxia 1% oxygen. In our xenograft experiments, HIF-1α deficient T-cells 
have increased tumors, probably due to, our defective cytokine and costimulatory 
effector profile being impaired. Thus, HIF-1α is necessary for proper CD8+ T-cell 
effector differentiation, with in vivo tumor killing capabilities being lessened, proving 
how cell type specific changes, modulate tumor progression.  
The effector molecules classically produced by CTLs such as TNFα, IFNᵧ and GmzB, 
were reduced in HIF-1α deficient T-cells, costimulatory and checkpoint molecules 
CD137, OX40, and GITR, and TIM3, CTLA-4, PD-1, and LAG-3, respectively, are 
also dependent upon HIF-1α in T-cells. Our previous findings could show PD-1 
downregulation was VHL regulated, but not ablated in the VHL/HIF-1α/ HIF-2α triple 
knockout cells (Doedens et al., 2013), however, in our HIF-1α deficient, tumor-
infiltrated cells, PD-1 levels were lower, compared to control, this could reflect model 
specific differences, such as inflammatory milieu between chronic viral load, and 
tumor engraftment. PD-1 regulation could also be hypoxia dependent, but not HIF-
1α dependent, as our ChIP-qPCR of wildtype mice could not detect any HIF-1α 
binding to the putative HRE of the PD-1 promoter.  
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There is a correlation between robust lymphocyte infiltration, and patient survival in 
a multitude of cancers, documented in melanoma, ovarian, head and neck cancer, 
breast, and colorectal (Galon et al., 2013). As we could observe, in our HIF-1α 
deficient T-cells, the tumor infiltration of CD8+ T-cells, was less compared to wildtype 
cells, accompanying lower PD-1 expression as well. Importantly, PD-1 levels in 
tumor-infiltrating T-cells, are associated with tumor reactive T-cell subsets (Gros et 
al., 2014). Furthermore, our HIF-1α deficient T-cells were impaired in their migration 
over endothelial barriers, which could possibly explain the low infiltration observed 
inside tumors.  
 
Immunotherapies are an emerging and exciting new field of cancer treatment, with 
the first PD-1L1 monoclonal antibody used in cancer therapeutics, as recently as 
2012 (Brahmer et al., 2012), with CTLA-4 monoclonal antibody therapy preceding 
only two years earlier (Hodi et al., 2010). We employed immunotherapy techniques 
to observe if HIF-1α was necessary for effector function. HIF-1α deficient T-cells 
seemed unaffected by the combinatorial immunotherapy, conversely, the wildtype 
cells responded to αCTLA-4/αPD-1 antibodies having smaller tumors. Thus, HIF-1α 
seems able to modulate immunotherapy-based modalities, which might be of clinical 
importance.  
 
As HIF-1α target genes are plentiful, one important and hallmark gene is VEGF-A. 
Our observations that VEGF-A is highly expressed by CD8+ T-cells during activation 
and was HIF-1α dependent, made us interested in the contribution of T-lymphocyte 
expressing VEGF-A during tumor progression. Our VEGF-A deficient T-cell mice, 
grew larger tumors, compared to control. The VEGF-A deficient T-cells activated 
properly, so we rule out cell-intrinsic effects in regards to overall T-cell biology. 
Furthermore, we also observed that VEGF-A deficient T-cells has less tumor 
infiltration, one important finding in regards to VEGF-A role in regulating 
tumor/endothelial cell barriers, and plays a role in the interactions between immune 
and vascular cells, stimulating recruitment (Melder et al., 1996; Detmar et al., 1998).  
The many effects of VEGF-A in these complex environments illustrates how 
important a factor it is, in regards to cell intrinsic loss, as well as, secretion from 
surrounding tumor microenvironment. VEGF-A deficient T-cells also seemed to 
normalize tumor vasculature, by increasing perfusion and oxygenation, with pericyte 
coverage also being increased on the vessels. Although, tumor vasculature is a 
hallmark of solid tumors, normalization of the vasculature is not always correlated to 
increases in tumor size (Carmeliet and Jain, 2011; Claesson-Welsh and Welsh, 
2013). Tumor vasculature is known to play important roles in regards to drug delivery 
and chemotherapy, as well as the oxygen status of the cells and surrounding tissues 
(Goel, Wong and Jain, 2012). In our VEGF-A deficient T-cells, chemotherapy 
administration, and probably delivery to the tumor, is more successful, in comparison 
to wildtype. The normalization of tumor vasculature, with increased perfusion and 
oxygen, likely contributes to these effects. In this complex tumor microenvironment, 
consisting of several other immunological components, macrophages have been 
shown to secrete VEGF-A, and with VEGF-A deletion in macrophages, susceptibility 
to chemotherapeutic cytotoxicity was also observed (Stockmann et al., 2008). 
Collectively, our findings demonstrate the importance of HIF-1α in the regulation of 
T-cell effector responses in the tumor microenvironment. Moreover, HIF-1α 
regulation of VEGF-A has functional consequences for effector CD8+ T-cells in 
infiltration, vascularization, and progression.    
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5.3 PAPER III (MANUSCRIPT) 
 
Today, we still lack an understanding of how 2-hydroxyglutaric acids (2-HG) affects 
the epigenome. 2-hydroxyglutaric acids have two enantiomers, R and S, and thus 
far, almost all studies have been focusing on the R-form of 2-HG, showing how R-
2HG is upregulated upon IDH1132 mutations (Dang et al., 2009). Further studies have 
implicated R and S-2HG in being histone lysine demethylase inhibitors (Chowdhury 
et al., 2011), JMJD2A and JMJD2C, albeit, at different potencies. Furthermore, 2-
oxoglutarate dependent enzymes, are affected by increased levels of R/S-2HG (Xu 
et al., 2011), by competitively binding to the 2-OG pocket and inhibiting the 
enzyme(s).   
 
The unsuspected finding, that S-2HG, decreases the overall acetylation level of 
histone N-terminal tails, is, previously, not known. Acetylation of histone proteins, 
neutralizes the overall positive charge of histone proteins, and by doing so, it loosens 
the interaction between DNA and the NCP (Verdone, Caserta and Mauro, 2005). 
This is believed to increase the access of transcription factors, and other chromatin 
binding proteins, to DNA (Castillo, López-Rodas and Franco, 2017). Hence, 
rendering an unattainable cis regulatory sequence, suddenly more accessible. Thus, 
these data imply that the HIF-1α/S-2HG axis induces changes in gene expression 
by lowering acetylation levels. It has previously been shown that differential H3K9Ac 
levels in CD8+ T-cells control the Eomes locus transcriptional output (Araki et al., 
2008). In the future, it would be interesting to combine our ChIP-seq analysis with 
gene-expression analysis, such as RNA-sequencing analysis, to identify acetylation-
regulated genes important for T-cell effector regulation.  
 
Previously it has been shown that S-2HG restrains cell expansion after 3 days of 
activation (Tyrakis et al., 2016) in accordance to our findings. The IL-7 receptor 
(CD127) has been shown to promote proliferation in virus specific CD8+ T-cells 
(Cellerai et al., 2010). We find that this gene had less acetylation during our S-2HG 
treatment compared to our vehicle control treated cells. This implies that at least 
some part of the suppression of proliferation may be driven through promoter 
acetylation of CD127.  
 
T-cell proliferation is controlled through multiple mechanisms and one important 
regulator of this is the PD-1 receptor and its cognate ligand PD-1L. S-2HG treated 
CD8+ T-cells express less PD-1 after 7 days of 500µM of S-2HG treatment (Tyrakis 
et al., 2016). We observe less promoter acetylation at the PD-1 promoter in 300µM 
S-2HG treated cells after 3 days of activation. This might indicate that acetylation is 
one mechanism of control over PD-1 expression in CD8+ T-cells.  
 
Acetylation and deacetylation of histone proteins are mediated through enzymatic 
reactions. We treated our CD8+ T-cell with TSA, which is a potent inhibitor of histone 
deacetylation, leading to an overall increase in H3K9Ac. Also under these conditions, 
S-2HG robustly decreased H3K9Ac.  
 
Several markers are associated with long term memory formation of T-cells, of which 
CD44 and CD62L seem to predict memory phenotypes, either TEM (CD62Llow 
CD127hi KLRG1hi CCR7low) or TCM (CD62Lhi CD44hi CD127hi CCR7hi KLRG1low) 
(Lazarevic, Glimcher and Lord, 2013). In our previous study, we could observe how 
S-2HG treatment increases the persistence and proportion of CD44hi Tcm memory 
cells after adoptive transfer experiments (Tyrakis et al., 2016). Our results however 
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show that the CD44 promoter after 3 days of activation in the presence of S-2HG is 
less acetylated, indicating that CD44 expression has decreased. The reasons for 
this potential discrepancy could be plentiful. Although acetylation is a good predictor 
of transcription, it might not be the sole determinant and thus CD44 expression might 
not be controlled through H3K9Ac. Moreover, the acetylation analysis of CD44 is 
performed at 3 days post activation whereas the adoptive transfer experiments in 
(Tyrakis et al., 2016) persisted for 30 days. Our ex vivo analysis is therefore difficult 
to compare with the in vivo experimental results. Careful mRNA analysis of the CD44 
gene during the course of T-cell activation with and without S-2HG treatment is 
therefore warranted.  
 
Collectively, our results show how acetylation is affected through S-2HG treatment 
of CD8+ T-cells, and thus provide a novel insight and potential modularity of effector 
differentiation through the addition of S-2HG during these processes.  
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CMB: This is where I started my journey, I am sorry in advance for people missed, not my 
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Tack för alla glada stunder och samtal, cica voli svoje male curice Jasmina & Maja.  
 
 
 
 
 
 

  41 
REFERENCES 
 
Akondy, R. S., Fitch, M., Edupuganti, S., Yang, S., Kissick, H. T., Li, K. W., Youngblood, 
B. A., Abdelsamed, H. A., McGuire, D. J., Cohen, K. W., Alexe, G., Nagar, S.,  
 
McCausland, M. M., Gupta, S., Tata, P., Haining, W. N., McElrath, M. J., Zhang, D., Hu, 
B., Greenleaf, W. J., Goronzy, J. J., Mulligan, M. J., Hellerstein, M. and Ahmed, R. (2017) 
‘Origin and differentiation of human memory CD8 T cells after vaccination’, Nature, 
552(7685), pp. 362–367. doi: 10.1038/nature24633. 
 
Akram, M. (2014) ‘Citric Acid Cycle and Role of its Intermediates in Metabolism’, Cell 
Biochemistry and Biophysics, 68(3), pp. 475–478. doi: 10.1007/s12013-013-9750-1. 
Andrews, F. H., Strahl, B. D. and Kutateladze, T. G. (2016) ‘Insights into newly discovered 
marks and readers of epigenetic information.’, Nature chemical biology. United States, 
12(9), pp. 662–668. doi: 10.1038/nchembio.2149. 
 
Araki, Y., Fann, M., Wersto, R. and Weng, N.-P. (2008) ‘Histone acetylation facilitates 
rapid and robust memory CD8 T cell response through differential expression of effector 
molecules (eomesodermin and its targets: perforin and granzyme B).’, Journal of 
immunology (Baltimore, Md. : 1950), 180(12), pp. 8102–8. doi: 
10.4049/jimmunol.180.12.8102. 
 
Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M. A., Bunn, H. 
F. and Livingston, D. M. (1996) ‘An essential role for p300/CBP in the cellular response to 
hypoxia.’, Proceedings of the National Academy of Sciences of the United States of 
America. United States, 93(23), pp. 12969–12973. 
 
Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G. and Påhlman, S. (2005) 
‘Hypoxia-induced dedifferentiation of tumor cells - A mechanism behind heterogeneity and 
aggressiveness of solid tumors’, Seminars in Cell and Developmental Biology, 16, pp. 554–
563. doi: 10.1016/j.semcdb.2005.03.007. 
 
Banks, R. E., Tirukonda, P., Taylor, C., Hornigold, N., Astuti, D., Cohen, D., Maher, E. R., 
Stanley, A. J., Harnden, P., Joyce, A., Knowles, M. and Selby, P. J. (2006) ‘Genetic and 
epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with 
clinical variables in sporadic renal cancer.’, Cancer research. United States, 66(4), pp. 
2000–2011. doi: 10.1158/0008-5472.CAN-05-3074. 
 
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C. 
and Kouzarides, T. (2001) ‘Selective recognition of methylated lysine 9 on histone H3 by 
the HP1 chromo domain.’, Nature. England, 410(6824), pp. 120–124. doi: 
10.1038/35065138. 
 
Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., Wei, G., 
Chepelev, I. and Zhao, K. (2007) ‘High-Resolution Profiling of Histone Methylations in the 
Human Genome’, Cell, 129(4), pp. 823–837. doi: 10.1016/j.cell.2007.05.009. 
Bell, O., Tiwari, V. K., Thomä, N. H. and Schübeler, D. (2011) ‘Determinants and 
dynamics of genome accessibility’, Nature Reviews Genetics. Nature Publishing Group, 
12(8), pp. 554–564. doi: 10.1038/nrg3017. 
 
 
 42 
Bert, A. G., Johnson, B. V, Baxter, E. W. and Cockerill, P. N. (2007) ‘A modular enhancer 
is differentially regulated by GATA and NFAT elements that direct different tissue-specific 
patterns of nucleosome positioning and inducible chromatin remodeling.’, Molecular and 
cellular biology. American Society for Microbiology Journals, 27(8), pp. 2870–85. doi: 
10.1128/MCB.02323-06. 
 
Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V. and Staller, P. (2008) ‘The 
histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-
inducible factor HIF.’, The Journal of biological chemistry, 283(52), pp. 36542–52. doi: 
10.1074/jbc.M804578200. 
 
Biju, M. P., Neumann, A. K., Bensinger, S. J., Johnson, R. S., Turka, L. A. and Haase, V. 
H. (2004) ‘Vhlh Gene Deletion Induces Hif-1-Mediated Cell Death in Thymocytes’, 
Molecular and Cellular Biology, 24(20), pp. 9038–9047. doi: 10.1128/MCB.24.20.9038-
9047.2004. 
 
Boyd, K. E. and Farnham, P. J. (1999) ‘Coexamination of Site-Specific Transcription 
Factor Binding and Promoter Activity in Living Cells’, Mol. Cell. Biol. American Society 
for Microbiology Journals, 19(12), pp. 8393–8399. doi: 10.1128/mcb.24.14.6127-
6139.2004. 
 
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., 
Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., 
Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., 
Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A. and Wigginton, J. 
M. (2012) ‘Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced 
Cancer’, New England Journal of Medicine, 366(26), pp. 2455–2465. doi: 
10.1056/NEJMoa1200694. 
 
Braun, S. M. G., Kirkland, J. G., Chory, E. J., Husmann, D., Calarco, J. P. and Crabtree, G. 
R. (2017) ‘Rapid and reversible epigenome editing by endogenous chromatin regulators’, 
Nature Communications. Springer US, 8(1). doi: 10.1038/s41467-017-00644-y. 
Carmeliet, P. and Jain, R. K. (2011) ‘Principles and mechanisms of vessel normalization for 
cancer and other angiogenic diseases’, Nature Reviews Drug Discovery, pp. 417–427. doi: 
10.1038/nrd3455. 
 
Castillo, J., López-Rodas, G. and Franco, L. (2017) ‘Histone post-translational 
modifications and nucleosome organisation in transcriptional regulation: Some open 
questions’, in Advances in Experimental Medicine and Biology, pp. 65–92. doi: 
10.1007/5584_2017_58. 
 
Cellerai, C., Perreau, M., Rozot, V., Enders, F. B., Pantaleo, G. and Harari, A. (2010) 
‘Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and 
Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7R (CD127) 
and Perforin Expression’, Journal of Virology, 84(8), pp. 3868–3878. doi: 
10.1128/JVI.02565-09. 
 
Chang, C. H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V, O’Sullivan, D., 
Huang, S. C. C., Van Der Windt, G. J. W., Blagih, J., Qiu, J., Weber, J. D., Pearce, E. J., 
Jones, R. G. and Pearce, E. L. (2013) ‘Posttranscriptional control of T cell effector function 
by aerobic glycolysis’, Cell, 153(6), pp. 1239–51. doi: 10.1016/j.cell.2013.05.016. 
Chen, C., Lou, T., Chen, C., Lou, T., Chen, C. and Lou, T. (2017) ‘Hypoxia inducible 
  43 
factors in hepatocellular carcinoma’, Oncotarget, 5(0), pp. 46691–46703. doi: 
10.18632/oncotarget.17358. 
 
Chen, H., Yan, Y., Davidson, T. L., Shinkai, Y. and Costa, M. (2006) ‘Hypoxic stress 
induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in 
mammalian cells.’, Cancer research, 66(18), pp. 9009–16. doi: 10.1158/0008-5472.CAN-
06-0101. 
 
Chen, T. and Dent, S. Y. R. (2014) ‘Chromatin modifiers and remodellers: regulators of 
cellular differentiation.’, Nature reviews. Genetics. Nature Publishing Group, 15(2), pp. 93–
106. doi: 10.1038/nrg3607. 
 
Chi, T. H., Wan, M., Zhao, K., Taniuchi, I., Chen, L., Littman, D. R., Crabtree, G. R., 
Bonaldi, T., Gunjan,  a, Bhattacharyya, N., Hock, R., Bustin, M., Nagata, S., Curnis, F., 
Corti,  a, Mu, S., Dellabona, P., Manfredi,  a and Pardi, R. (2002) ‘Reciprocal regulation of 
CD4 / CD8 expression by SWI / SNF-like BAF complexes’, Nature, 418(July), pp. 195–
199. doi: 10.1038/nature00858.1. 
 
Chisolm, D. A. and Weinmann, A. S. (2015) ‘TCR-signaling events in cellular metabolism 
and specialization’, Frontiers in Immunology, 6(JUN), pp. 10–14. doi: 
10.3389/fimmu.2015.00292. 
 
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. 
K. H., Li, X. S., Woon, E. C. Y., Yang, M., McDonough, M. A., King, O. N., Clifton, I. J., 
Klose, R. J., Claridge, T. D. W., Ratcliffe, P. J., Schofield, C. J. and Kawamura, A. (2011) 
‘The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.’, EMBO 
reports. Nature Publishing Group, 12(5), pp. 463–9. doi: 10.1038/embor.2011.43. 
 
Cieniewicz, A. M., Moreland, L., Ringel, A. E., Mackintosh, S. G., Raman, A., Gilbert, T. 
M., Wolberger, C., Tackett, A. J. and Taverna, S. D. (2014) ‘The bromodomain of Gcn5 
regulates site specificity of lysine acetylation on histone H3.’, Molecular & cellular 
proteomics : MCP. United States, 13(11), pp. 2896–2910. doi: 10.1074/mcp.M114.038174. 
Claesson-Welsh, L. and Welsh, M. (2013) ‘VEGFA and tumour angiogenesis’, Journal of 
Internal Medicine, pp. 114–127. doi: 10.1111/joim.12019. 
 
Clark, M. D., Marcum, R., Graveline, R., Chan, C. W., Xie, T., Chen, Z., Ding, Y., Zhang, 
Y., Mondragón, A., David, G. and Radhakrishnan, I. (2015) ‘Structural insights into the 
assembly of the histone deacetylase-associated Sin3L/Rpd3L corepressor complex’, 
Proceedings of the National Academy of Sciences. National Academy of Sciences, 112(28), 
pp. E3669–E3678. doi: 10.1073/pnas.1504021112. 
 
Clever, D., Roychoudhuri, R., Constantinides, M. G., Askenase, M. H., Sukumar, M., 
Klebanoff, C. A., Eil, R. L., Hickman, H. D., Yu, Z., Pan, J. H., Palmer, D. C., Phan, A. T., 
Goulding, J., Gattinoni, L., Goldrath, A. W., Belkaid, Y. and Restifo, N. P. (2016) ‘Oxygen 
Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche’, Cell, 
166(5), p. 1117–1131.e14. doi: 10.1016/j.cell.2016.07.032. 
 
Crompton, J. G., Narayanan, M., Cuddapah, S., Roychoudhuri, R., Ji, Y., Yang, W., Patel, 
S. J., Sukumar, M., Palmer, D. C., Peng, W., Wang, E., Marincola, F. M., Klebanoff, C. A., 
Zhao, K., Tsang, J. S., Gattinoni, L. and Restifo, N. P. (2016) ‘Lineage relationship of 
CD8+T cell subsets is revealed by progressive changes in the epigenetic landscape’, 
Cellular and Molecular Immunology. Nature Publishing Group, 13(4), pp. 502–513. doi: 
 44 
10.1038/cmi.2015.32. 
Dang, E. V, Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., 
Kim, Y., Yen, H.-R., Luo, W., Zeller, K., Shimoda, L., Topalian, S. L., Semenza, G. L., 
Dang, C. V, Pardoll, D. M. and Pan, F. (2011) ‘Control of T(H)17/T(reg) balance by 
hypoxia-inducible factor 1.’, Cell. United States, 146(5), pp. 772–784. doi: 
10.1016/j.cell.2011.07.033. 
 
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, 
V. R., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., Prins, R. M., Ward, P. S., Yen, K. 
E., Liau, L. M., Rabinowitz, J. D., Cantley, L. C., Thompson, C. B., Vander Heiden, M. G. 
and Su, S. M. (2009) ‘Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.’, 
Nature. Nature Publishing Group, 462(7274), pp. 739–44. doi: 10.1038/nature08617. 
 
Detmar, M., Brown, L. F., Schön, M. P., Elicker, B. M., Velasco, P., Richard, L., 
Fukumura, D., Monsky, W., Claffey, K. P. and Jain, R. K. (1998) ‘Increased microvascular 
density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice’, 
Journal of Investigative Dermatology, 111(1), pp. 1–6. doi: 10.1046/j.1523-
1747.1998.00262.x. 
 
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K. and Zhou, M. M. (1999) 
‘Structure and ligand of a histone acetyltransferase bromodomain.’, Nature. England, 
399(6735), pp. 491–496. doi: 10.1038/20974. 
 
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V, Yang, E., 
Johnson, R. S. and Goldrath, A. W. (2013) ‘Hypoxia-inducible factors enhance the effector 
responses of CD8 + T cells to persistent antigen’, Nature Immunology, 14(11), pp. 1173–
1182. doi: 10.1038/ni.2714. 
 
Du, R., Xia, L., Ning, X., Liu, L., Sun, W., Huang, C., Wang, H. and Sun, S. (2014) 
‘Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and 
renal fibrosis via PI3K/Akt signal.’, Molecular biology of the cell. United States, 25(17), 
pp. 2650–2659. doi: 10.1091/mbc.E14-01-0044. 
 
Dunaief, J. L., Strober, B. E., Guha, S., Khavari, P. a, Alin, K., Luban, J., Begemann, M., 
Crabtree, G. R. and Goff, S. P. (1994) ‘The retinoblastoma protein and BRG1 form a 
complex and cooperate to induce cell cycle arrest.’, Cell, 79, pp. 119–130. doi: 0092-
8674(94)90405-7 [pii]. 
 
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, 
N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. 
K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., L??wenberg, B., Licht, J. D., Godley, L. 
A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L. and Melnick, A. (2010) 
‘Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt 
TET2 Function, and Impair Hematopoietic Differentiation’, Cancer Cell, 18(6), pp. 553–
567. doi: 10.1016/j.ccr.2010.11.015. 
 
Galon, J., Angell, H. K., Bedognetti, D. and Marincola, F. M. (2013) ‘The Continuum of 
Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures’, 
Immunity, 39(1), pp. 11–26. doi: 10.1016/j.immuni.2013.07.008. 
 
 
 
  45 
Goel, S., Wong, A. H. K. and Jain, R. K. (2012) ‘Vascular normalization as a therapeutic 
strategy for malignant and nonmalignant disease’, Cold Spring Harbor Perspectives in 
Medicine, 2(3), p. a006486. doi: 10.1101/cshperspect.a006486. 
 
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., 
Mixon, A., Farid, S., Dudley, M. E., Hanada, K. I., Almeida, J. R., Darko, S., Douek, D. C., 
Yang, J. C. and Rosenberg, S. A. (2014) ‘PD-1 identifies the patient-specific CD8+tumor-
reactive repertoire infiltrating human tumors’, Journal of Clinical Investigation, 124(5), pp. 
2246–2259. doi: 10.1172/JCI73639. 
 
Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. and Bradfield, C. A. (1998) 
‘Molecular characterization and chromosomal localization of a third alpha-class hypoxia 
inducible factor subunit, HIF3alpha.’, Gene expression. United States, 7(3), pp. 205–213. 
Hanahan, D. and Coussens, L. M. (2012) ‘Accessories to the crime: functions of cells 
recruited to the tumor microenvironment.’, Cancer cell. United States, 21(3), pp. 309–322. 
doi: 10.1016/j.ccr.2012.02.022. 
 
Hanahan, D. and Weinberg, R. A. (2011) ‘Hallmarks of cancer: the next generation.’, Cell, 
144(5), pp. 646–74. doi: 10.1016/j.cell.2011.02.013. 
 
Hatzimichael, E., Dasoula, A., Shah, R., Syed, N., Papoudou-Bai, A., Coley, H. M., 
Dranitsaris, G., Bourantas, K. L., Stebbing, J. and Crook, T. (2010) ‘The prolyl-
hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell 
neoplasia.’, European journal of haematology. England, 84(1), pp. 47–51. doi: 
10.1111/j.1600-0609.2009.01344.x. 
 
Hatzimichael, E., Dranitsaris, G., Dasoula, A., Benetatos, L., Stebbing, J., Crook, T. and 
Bourantas, K. L. (2009) ‘Von Hippel-Lindau methylation status in patients with multiple 
myeloma: a potential predictive factor for the development of bone disease.’, Clinical 
lymphoma & myeloma. United States, 9(3), pp. 239–242. doi: 10.3816/CLM.2009.n.047. 
 
He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., 
Sun, Y., Li, X., Dai, Q., Song, C.-X., Zhang, K., He, C. and Xu, G.-L. (2011) ‘Tet-
mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.’, 
Science (New York, N.Y.). United States, 333(6047), pp. 1303–1307. doi: 
10.1126/science.1210944. 
 
Henning, A. N., Roychoudhuri, R. and Restifo, N. P. (2018) ‘Epigenetic control of CD8+ T 
cell differentiation’, Nature Reviews Immunology. Nature Publishing Group. doi: 
10.1038/nri.2017.146. 
 
Ho, L., Miller, E. L., Ronan, J. L., Ho, W. Q., Jothi, R. and Crabtree, G. R. (2011) ‘esBAF 
facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by 
regulating polycomb function.’, Nature cell biology. Nature Publishing Group, 13(8), pp. 
903–913. doi: 10.1038/ncb2285. 
 
Hodi, F. S., Day, S. J. O., Mcdermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., 
Gonzalez, R., Ph, D., Schadendorf, D., Hassel, J. C., Akerley, W., Eertwegh, A. J. M. Van 
Den, Ph, D., Lutzky, J., Lorigan, P., Ph, D., Lebbé, C., Peschel, C. and Quirt, I. (2010) 
‘Improved Survival with Ipilimumab in Patients with Metastatic Melanoma’, New England 
Journal of Medicine, 363(8), pp. 711–723. doi: 10.1056/NEJMoa1003466.Improved. 
 
 46 
Holmes, S., He, M., Xu, T. and Lee, P. P. (2005) ‘Memory T cells have gene expression 
patterns intermediate between naive and effector’, Proceedings of the National Academy of 
Sciences, 102(15), pp. 5519–5523. doi: 10.1073/pnas.0501437102. 
 
Hu, C., Wang, L., Chodosh, L. a, Keith, B. and Simon, M. C. (2003) ‘Differential Roles of 
Hypoxia-Inducible Factor 1 alpha ( HIF-1 alpha ) and HIF-2 alpha in Hypoxic Gene 
Regulation.’, Molecular and Cellular Biology, 23(24), pp. 9361–9374. doi: 
10.1128/MCB.23.24.9361. 
 
Huang, L. E., Gu, J., Schau, M. and Bunn, H. F. (1998) ‘Regulation of hypoxia-inducible 
factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-
proteasome pathway.’, Proceedings of the National Academy of Sciences of the United 
States of America, 95(14), pp. 7987–92. Available at:  
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=20916&tool=pmcentrez&rende
rtype=abstract (Accessed: 12 February 2015). 
 
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-
Maoz, B., Pang, J., Chmielowski, B., Cherry, G., Seja, E., Lomeli, S., Kong, X., Kelley, M. 
C., Sosman, J. A., Johnson, D. B., Ribas, A. and Lo, R. S. (2016) ‘Genomic and 
Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.’, 
Cell. United States, 165(1), pp. 35–44. doi: 10.1016/j.cell.2016.02.065. 
 
Intlekofer, A. M., DeMatteo, R. G., Venneti, S., Finley, L. W. S., Lu, C., Judkins, A. R., 
Rustenburg, A. S., Grinaway, P. B., Chodera, J. D., Cross, J. R. and Thompson, C. B. 
(2015) ‘Hypoxia Induces Production of L-2-Hydroxyglutarate’, Cell Metabolism, 22(2), pp. 
304–311. doi: 10.1016/j.cmet.2015.06.023. 
 
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C. and Zhang, Y. 
(2011) ‘Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-
carboxylcytosine.’, Science (New York, N.Y.). United States, 333(6047), pp. 1300–1303. 
doi: 10.1126/science.1210597. 
 
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., 
Lane, W. S. and Kaelin, W. G. (2001) ‘HIFalpha targeted for VHL-mediated destruction by 
proline hydroxylation: implications for O2 sensing.’, Science (New York, N.Y.), 292(5516), 
pp. 464–8. doi: 10.1126/science.1059817. 
 
Iyer, N. V, Leung, S. W. and Semenza, G. L. (1998) ‘The human hypoxia-inducible factor 
1alpha gene: HIF1A structure and evolutionary conservation.’, Genomics, 52, pp. 159–165. 
doi: 10.1006/geno.1998.5416. 
 
Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., von 
Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. 
W. and Ratcliffe, P. J. (2001) ‘Targeting of HIF-alpha to the von Hippel-Lindau 
ubiquitylation complex by O2-regulated prolyl hydroxylation.’, Science (New York, N.Y.), 
292(5516), pp. 468–72. doi: 10.1126/science.1059796. 
 
Jiang, B. H., Rue, E., Wang, G. L., Roe, R. and Semenza, G. L. (1996) ‘Dimerization, DNA 
binding, and transactivation properties of hypoxia-inducible factor 1.’, The Journal of 
biological chemistry, 271(30), pp. 17771–8. Available at:  
http://www.ncbi.nlm.nih.gov/pubmed/8663540 (Accessed: 10 December 2013). 
 
  47 
Jiang, L., Greenwood, T. R., Artemov, D., Raman, V., Winnard, P. T., Heeren, R. M. A., 
Bhujwalla, Z. M. and Glunde, K. (2012) ‘Localized Hypoxia Results in Spatially 
Heterogeneous Metabolic Signatures in Breast Tumor Models’, Neoplasia, 14(8), pp. 732–
741. doi: 10.1593/neo.12858. 
 
Jogi, A., Ora, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L., Axelson, H. and 
Pahlman, S. (2002) ‘Hypoxia alters gene expression in human neuroblastoma cells toward 
an immature and neural crest-like phenotype’, Proceedings of the National Academy of 
Sciences, 99(10), pp. 7021–7026. doi: 10.1073/pnas.102660199. 
 
John, S., Sabo, P. J., Canfield, T. K., Lee, K., Vong, S., Weaver, M., Wang, H., Vierstra, J., 
Reynolds, A. P., Thurman, R. E. and Stamatoyannopoulos, J. A. (2013) ‘Genome-scale 
mapping of DNase I hypersensitivity.’, Current protocols in molecular biology. United 
States, Chapter 27, p. Unit 21.27. doi: 10.1002/0471142727.mb2127s103. 
 
Kallio, P. J., Okamoto, K., O’Brien, S., Carrero, P., Makino, Y., Tanaka, H. and Poellinger, 
L. (1998) ‘Signal transduction in hypoxic cells: inducible nuclear translocation and 
recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha.’, The 
EMBO journal, 17(22), pp. 6573–86. doi: 10.1093/emboj/17.22.6573. 
 
Kallio, P. J., Wilson, W. J., O’Brien, S., Makino, Y. and Poellinger, L. (1999) ‘Regulation 
of the hypoxia-inducible transcription factor 1 alpha by the ubiquitin-proteasome pathway’, 
Journal of Biological Chemistry, 274(10), pp. 6519–6525. doi: 10.1074/jbc.274.10.6519. 
 
Kato, H., Tamamizu-Kato, S. and Shibasaki, F. (2004) ‘Histone deacetylase 7 associates 
with hypoxia-inducible factor 1alpha and increases transcriptional activity.’, The Journal of 
biological chemistry. United States, 279(40), pp. 41966–41974. doi: 
10.1074/jbc.M406320200. 
 
Keith, B., Johnson, R. S. and Simon, M. C. (2011) ‘HIF1α and HIF2α: sibling rivalry in 
hypoxic tumour growth and progression’, Nature Reviews Cancer, 12(1), pp. 9–22. doi: 
10.1038/nrc3183. 
 
Kenneth, N. S., Mudie, S., van Uden, P. and Rocha, S. (2009) ‘SWI/SNF regulates the 
cellular response to hypoxia.’, The Journal of biological chemistry. United States, 284(7), 
pp. 4123–4131. doi: 10.1074/jbc.M808491200. 
 
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., 
Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., 
Verhaak, R. G. W., Yan, H. and Kaelin Jr, W. G. (2012) ‘Transformation by the (R)-
enantiomer of 2-hydroxyglutarate linked to EGLN activation’, Nature, 483(7390), pp. 484–
488. doi: 10.1038/nature10898. 
 
Lachance, G., Uniacke, J., Audas, T. E., Holterman, C. E., Franovic, A., Payette, J. and 
Lee, S. (2014) ‘DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing 
pathway and the cellular response to hypoxia.’, Proceedings of the National Academy of 
Sciences of the United States of America, p. 1322909111-. doi: 10.1073/pnas.1322909111. 
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L. and Bruick, R. K. 
(2002) ‘FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional 
activity of hypoxia-inducible factor.’, Genes & development, 16(12), pp. 1466–71. doi: 
10.1101/gad.991402. 
 
 48 
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. and Whitelaw, M. L. (2002) 
‘Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.’, Science 
(New York, N.Y.), 295(5556), pp. 858–61. doi: 10.1126/science.1068592. 
 
Lazarevic, V., Glimcher, L. H. and Lord, G. M. (2013) ‘T-bet: a bridge between innate and 
adaptive immunity.’, Nature reviews. Immunology. Nature Publishing Group, 13(11), pp. 
777–89. doi: 10.1038/nri3536. 
 
Lessard, J. a and Crabtree, G. R. (2010) ‘Chromatin regulatory mechanisms in 
pluripotency.’, Annual review of cell and developmental biology, 26, pp. 503–532. doi: 
10.1146/annurev-cellbio-051809-102012. 
 
Li, X., Egervari, G., Wang, Y., Berger, S. L. and Lu, Z. (2018) ‘Regulation of chromatin 
and gene expression by metabolic enzymes and metabolites.’, Nature reviews. Molecular 
cell biology. England. doi: 10.1038/s41580-018-0029-7. 
 
Lieb, J. D., Liu, X., Botstein, D. and Brown, P. O. (2001) ‘Promoter-specific binding of 
Rap1 revealed by genome-wide maps of protein-DNA association’, Nature Genetics, 28(4), 
pp. 327–334. doi: 10.1038/ng569. 
 
Lu, Y., Chu, A., Turker, M. S. and Glazer, P. M. (2011) ‘Hypoxia-Induced Epigenetic 
Regulation and Silencing of the BRCA1 Promoter’, Molecular and Cellular Biology. 
American Society for Microbiology, 31(16), pp. 3339–3350. doi: 10.1128/MCB.01121-10. 
Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F. and Richmond, T. J. (1997) 
‘Crystal structure of the nucleosome core particle at 2.8 A resolution.’, Nature. England, 
389(6648), pp. 251–260. doi: 10.1038/38444. 
 
Lundby, C., Calbet, J. A. L. and Robach, P. (2009) ‘The response of human skeletal muscle 
tissue to hypoxia’, Cellular and Molecular Life Sciences, 66(22), pp. 3615–3623. doi: 
10.1007/s00018-009-0146-8. 
 
Mahon, P. C., Hirota, K. and Semenza, G. L. (2001) ‘FIH-1: a novel protein that interacts 
with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.’, Genes 
& development, 15(20), pp. 2675–86. doi: 10.1101/gad.924501. 
 
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., 
Berkenstam, A. and Poellinger, L. (2001) ‘Inhibitory PAS domain protein is a negative 
regulator of hypoxia-inducible gene expression.’, Nature. England, 414(6863), pp. 550–
554. doi: 10.1038/35107085. 
 
Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. 
E., Wykoff, C. C., Pugh, C. W., Maher, E. R. and Ratcliffe, P. J. (1999) ‘The tumour 
suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent 
proteolysis.’, Nature, 399(6733), pp. 271–5. doi: 10.1038/20459. 
 
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway, R. C., 
Conaway, J. W. and Ohh, M. (2003) ‘Multiple splice variants of the human HIF-3 alpha 
locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.’, The Journal of 
biological chemistry. United States, 278(13), pp. 11032–11040. doi: 
10.1074/jbc.M208681200. 
 
 
  49 
McDonel, P., Costello, I. and Hendrich, B. (2009) ‘Keeping things quiet: Roles of NuRD 
and Sin3 co-repressor complexes during mammalian development’, International Journal 
of Biochemistry and Cell Biology. Europe PMC Funders, pp. 108–116. doi: 
10.1016/j.biocel.2008.07.022. 
 
Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L. and Jain, R. K. 
(1996) ‘During angiogenesis, vascular endothelial growth factor and basic fibroblast growth 
factor regulate natural killer cell adhesion to tumor endothelium’, Nature Medicine, 2(9), 
pp. 992–997. doi: 10.1038/nm0996-992. 
 
Van Der Merwe, P. A. and Dushek, O. (2011) ‘Mechanisms for T cell receptor triggering’, 
Nature Reviews Immunology. Nature Publishing Group, pp. 47–55. doi: 10.1038/nri2887. 
Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C. and 
Tanaka, H. (2005) ‘TCR engagement increases hypoxia-inducible factor-1 alpha protein 
synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T 
cells.’, Journal of immunology (Baltimore, Md. : 1950), 174(12), pp. 7592–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15944259 (Accessed: 31 May 2018). 
 
Nobre, A. R., Entenberg, D., Wang, Y., Condeelis, J. and Aguirre-Ghiso, J. A. (2018) ‘The 
Different Routes to Metastasis via Hypoxia-Regulated Programs’, Trends in Cell Biology, 
21 July. doi: 10.1016/j.tcb.2018.06.008. 
 
Oldham, W. M., Clish, C. B., Yang, Y. and Loscalzo, J. (2015) ‘Hypoxia-Mediated 
Increases in l-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress’, 
Cell Metabolism. Elsevier Inc., 22(2), pp. 291–303. doi: 10.1016/j.cmet.2015.06.021. 
 
Opferman, J. T., Ober, B. T. and Ashton-Rickardt, P. G. (1999) ‘Linear differentiation of 
cytotoxic effectors into memory T lymphocytes’, Science, 283(5408), pp. 1745–1748. doi: 
10.1126/science.283.5408.1745. 
 
Oskarsson, T., Batlle, E. and Massagué, J. (2014) ‘Metastatic stem cells: Sources, niches, 
and vital pathways’, Cell Stem Cell. Cell Press, pp. 306–321. doi: 
10.1016/j.stem.2014.02.002. 
 
Pace, L., Goudot, C., Zueva, E., Gueguen, P., Burgdorf, N., Waterfall, J. J., Quivy, J.-P., 
Almouzni, G. and Amigorena, S. (2018) ‘The epigenetic control of stemness in CD8+T cell 
fate commitment.’, Science (New York, N.Y.), 359(6372), pp. 177–186. doi: 
10.1126/science.aah6499. 
 
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G. 
and Choi, Y. (2009) ‘Enhancing CD8 T-cell memory by modulating fatty acid 
metabolism.’, Nature. England, 460(7251), pp. 103–107. doi: 10.1038/nature08097. 
 
Peng, J., Zhang, L., Drysdale, L. and Fong, G. H. (2000) ‘The transcription factor EPAS-
1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling.’, 
Proceedings of the National Academy of Sciences of the United States of America. National 
Academy of Sciences, 97(15), pp. 8386–91. doi: 10.1073/pnas.140087397. 
 
Platt, J. L., Salama, R., Smythies, J., Choudhry, H., Davies, J. O. J., Hughes, J. R., 
Ratcliffe, P. J. and Mole, D. R. (2016) ‘Capture-C reveals preformed chromatin interactions 
between HIF-binding sites and distant promoters’, EMBO reports, 17(10), p. 1410 LP-
1421. Available at: http://embor.embopress.org/content/17/10/1410.abstract. 
 50 
Politz, J. C. R., Scalzo, D. and Groudine, M. (2013) ‘Something silent this way forms: the 
functional organization of the repressive nuclear compartment.’, Annual review of cell and 
developmental biology, 29, pp. 241–70. doi: 10.1146/annurev-cellbio-101512-122317. 
 
Qiu, G. Z., Jin, M. Z., Dai, J. X., Sun, W., Feng, J. H. and Jin, W. L. (2017)  
‘Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and 
Associated Therapeutic Strategies’, Trends in Pharmacological Sciences. Elsevier Ltd, 
38(8), pp. 669–686. doi: 10.1016/j.tips.2017.05.002. 
 
Rankin, E. B., Nam, J.-M. and Giaccia, A. J. (2016) ‘Hypoxia: Signaling the Metastatic 
Cascade.’, Trends in cancer. United States, 2(6), pp. 295–304. doi: 
10.1016/j.trecan.2016.05.006. 
 
Rey, S. and Semenza, G. L. (2010) ‘Hypoxia-inducible factor-1-dependent mechanisms of 
vascularization and vascular remodelling’, Cardiovascular Research, 86(2), pp. 236–242. 
doi: 10.1093/cvr/cvq045. 
 
Rhee, H. S., Bataille, A. R., Zhang, L. and Pugh, B. F. (2014) ‘Subnucleosomal Structures 
and Nucleosome Asymmetry across a Genome’, Cell, 159(6), pp. 1377–1388. doi: 
10.1016/j.cell.2014.10.054. 
 
Roychoudhuri, R., Lefebvre, F., Honda, M., Pan, L., Ji, Y., Klebanoff, C. A., Nichols, C. 
N., Fourati, S., Hegazy, A. N., Goulet, J. P., Gattinoni, L., Nabel, G. J., Gilliet, M., 
Cameron, M., Restifo, N. P., Sï¿½kaly, R. P. and Flatz, L. (2015) ‘Transcriptional profiles 
reveal a stepwise developmental program of memory CD8+T cell differentiation’, Vaccine, 
33(7), pp. 914–923. doi: 10.1016/j.vaccine.2014.10.007. 
 
Sabari, B. R., Zhang, D., Allis, C. D. and Zhao, Y. (2016) ‘Metabolic regulation of gene 
expression through histone acylations’, Nature Reviews Molecular Cell Biology. Nature 
Publishing Group, 18(2), pp. 90–101. doi: 10.1038/nrm.2016.140. 
 
Scharer, C. D., Barwick, B. G., Youngblood, B. A., Ahmed, R. and Boss, J. M. (2013) 
‘Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function’, The 
Journal of Immunology, 191(6), pp. 3419–3429. doi: 10.4049/jimmunol.1301395. 
 
Schito, L. and Semenza, G. L. (2016) ‘Hypoxia-Inducible Factors: Master Regulators of 
Cancer Progression’, Trends in Cancer. Elsevier Inc., 2(12), pp. 758–770. doi: 
10.1016/j.trecan.2016.10.016. 
 
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J. and Mole, D. 
R. (2011) ‘High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq’, 
Blood, 117(23), pp. 207–218. doi: 10.1182/blood-2010-10-314427. 
 
Semenza, G. L. (2014) ‘Oxygen Sensing, Hypoxia-Inducible Factors, and Disease 
Pathophysiology’, Annual Review of Pathology: Mechanisms of Disease, 9(1), pp. 47–71. 
doi: 10.1146/annurev-pathol-012513-104720. 
 
Shahrzad, S., Bertrand, K., Minhas, K. and Coomber, B. (2007) ‘Induction of DNA 
Hypomethylation by Tumor Hypoxia’, Epigenetics. Taylor & Francis, 2(2), pp. 119–125. 
doi: 10.4161/epi.2.2.4613. 
 
 
  51 
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S. and Kaelin, 
W. G. (2011) ‘Genetic and functional studies implicate HIF1α as a 14q kidney cancer 
suppressor gene.’, Cancer discovery, 1(3), pp. 222–35. doi: 10.1158/2159-8290.CD-11-
0098. 
 
Shen, C. and Kaelin, W. G. (2013) ‘The VHL/HIF axis in clear cell renal carcinoma’, 
Seminars in Cancer Biology. Elsevier Ltd, 23(1), pp. 18–25. doi: 
10.1016/j.semcancer.2012.06.001. 
 
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R. and Chi, H. (2011) 
‘HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the 
differentiation of TH17 and Treg cells.’, The Journal of experimental medicine. Rockefeller 
University Press, 208(7), pp. 1367–76. doi: 10.1084/jem.20110278. 
 
Siegel, R. L., Miller, K. D. and Jemal, A. (2018) ‘Cancer statistics, 2018’, CA: A Cancer 
Journal for Clinicians, 68(1), pp. 7–30. doi: 10.3322/caac.21442. 
 
Smith-Garvin, J. and Koretzky, G. (2009) ‘T cell activation’, Annual Review of 
Immunology, 27, pp. 591–619. doi: 10.1146/annurev.immunol.021908.132706.T. 
 
Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., 
Cheresh, D. A. and Johnson, R. S. (2008) ‘Deletion of vascular endothelial growth factor in 
myeloid cells accelerates tumorigenesis’, Nature, 456(7223), pp. 814–819. doi: 
10.1038/nature07445. 
 
Swygert, S. G. and Peterson, C. L. (2014) ‘Chromatin dynamics: Interplay between 
remodeling enzymes and histone modifications’, Biochimica et Biophysica Acta - Gene 
Regulatory Mechanisms. Elsevier B.V., 1839(8), pp. 728–736. doi: 
10.1016/j.bbagrm.2014.02.013. 
 
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, 
S., Iyer, L. M., Liu, D. R., Aravind, L. and Rao, A. (2009) ‘Conversion of 5-methylcytosine 
to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.’, Science (New 
York, N.Y.). United States, 324(5929), pp. 930–935. doi: 10.1126/science.1170116. 
 
Talbert, P. B. and Henikoff, S. (2017) ‘Histone variants on the move: Substrates for 
chromatin dynamics’, Nature Reviews Molecular Cell Biology. Nature Publishing Group, 
18(2), pp. 115–126. doi: 10.1038/nrm.2016.148. 
 
Tanaka, T., Wiesener, M., Bernhardt, W., Eckardt, K.-U. and Warnecke, C. (2009) ‘The 
human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may 
modulate hypoxic gene induction.’, The Biochemical journal. England, 424(1), pp. 143–
151. doi: 10.1042/BJ20090120. 
 
Tang, J., Yoo, A. S. and Crabtree, G. R. (2013) ‘Reprogramming human fibroblasts to 
neurons by recapitulating an essential microRNA-chromatin switch.’, Current opinion in 
genetics & development, 23(5), pp. 591–8. doi: 10.1016/j.gde.2013.07.001. 
 
Taylor, C. T. and Colgan, S. P. (2017) ‘Regulation of immunity and inflammation by 
hypoxia in immunological niches’, Nature Reviews Immunology. Nature Publishing Group, 
17(12), pp. 774–785. doi: 10.1038/nri.2017.103. 
 
 52 
Tian, H., McKnight, S. L. and Russell, D. W. (1997) ‘Endothelial PAS domain protein 1 
(EPAS1), a transcription factor selectively expressed in endothelial cells.’, Genes & 
development, 11(1), pp. 72–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9000051 (Accessed: 23 January 2015). 
 
Towbin, B. D., González-Aguilera, C., Sack, R., Gaidatzis, D., Kalck, V., Meister, P., 
Askjaer, P. and Gasser, S. M. (2012) ‘Step-wise methylation of histone H3K9 positions 
heterochromatin at the nuclear periphery.’, Cell, 150(5), pp. 934–47. doi: 
10.1016/j.cell.2012.06.051. 
 
Tyrakis, P. A., Palazon, A., Macias, D., Lee, K. L., Phan, A. T., Veliça, P., You, J., Chia, 
G. S., Sim, J., Doedens, A., Abelanet, A., Evans, C. E., Griffiths, J. R., Poellinger, L., 
Goldrath, A. W. and Johnson, R. S. (2016) ‘S-2-hydroxyglutarate regulates CD8+ T-
lymphocyte fate’, Nature. Nature Publishing Group, 540(7632), pp. 236–241. doi: 
10.1038/nature20165. 
 
Ueda, J., Ho, J. C., Lee, K. L., Kitajima, S., Yang, H., Sun, W., Fukuhara, N., Zaiden, N., 
Chan, S. L., Tachibana, M., Shinkai, Y., Kato, H. and Poellinger, L. (2014) ‘The Hypoxia-
Inducible Epigenetic Regulators Jmjd1a and G9a Provide a Mechanistic Link between 
Angiogenesis and Tumor Growth.’, Molecular and cellular biology, 34(19), pp. 3702–
3720. doi: 10.1128/MCB.00099-14. 
 
Vaupel, P. and Mayer, A. (2007) ‘Hypoxia in cancer: Significance and impact on clinical 
outcome’, Cancer and Metastasis Reviews, pp. 225–239. doi: 10.1007/s10555-007-9055-1. 
Venkatesh, S. and Workman, J. L. (2015) ‘Histone exchange, chromatin structure and the 
regulation of transcription’, Nature Reviews Molecular Cell Biology. Nature Publishing 
Group, 16(3), pp. 178–189. doi: 10.1038/nrm3941. 
 
Verdone, L., Caserta, M. and Mauro, E. Di (2005) ‘Role of histone acetylation in the 
control of gene expression’, Biochemistry and Cell Biology, 83(3), pp. 344–353. doi: 
10.1139/o05-041. 
 
Wang, G. L., Jiang, B. H., Rue, E. A. and Semenza, G. L. (1995) ‘Hypoxia-inducible factor 
1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.’, 
Proceedings of the National Academy of Sciences of the United States of America, 92(12), 
pp. 5510–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7539918 (Accessed: 23 
January 2015). 
 
Wang, G. L. and Semenza, G. L. (1993) ‘Characterization of hypoxia-inducible factor 1 and 
regulation of DNA binding activity by hypoxia.’, The Journal of biological chemistry, 
268(29), pp. 21513–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8408001 
(Accessed: 10 December 2013). 
 
Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K. A., Wilkerson, M. D., Perou, C. 
M., Guan, K. L., Ye, D. and Xiong, Y. (2015) ‘Oncometabolite D-2-Hydroxyglutarate 
Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating 
Agents’, Cell Reports. The Authors, 13(11), pp. 2353–2361. doi: 
10.1016/j.celrep.2015.11.029. 
 
Wang, X., Haswell, J. R. and Roberts, C. W. M. (2014) ‘Molecular pathways: SWI/SNF 
(BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic 
insights.’, Clinical cancer research : an official journal of the American Association for 
  53 
Cancer Research. United States, 20(1), pp. 21–27. doi: 10.1158/1078-0432.CCR-13-0280. 
Waterborg, J. H. (2012) ‘Evolution of histone H3: emergence of variants and conservation 
of post-translational modification sites.’, Biochemistry and cell biology = Biochimie et 
biologie cellulaire. Canada, 90(1), pp. 79–95. doi: 10.1139/o11-036. 
 
Wellmann, S., Bettkober, M., Zelmer, A., Seeger, K., Faigle, M., Eltzschig, H. K. and 
Bührer, C. (2008) ‘Hypoxia upregulates the histone demethylase JMJD1A via HIF-1’, 
Biochemical and Biophysical Research Communications, 372, pp. 892–897. doi: 
10.1016/j.bbrc.2008.05.150. 
 
WIESENER, M. S., JÜRGENSEN, J. A. N. S., ROSENBERGER, C., SCHOLZE, C. K., 
HÖRSTRUP, J. A. N. H., WARNECKE, C., MANDRIOTA, S., BECHMANN, I., FREI, 
U. A., PUGH, C. W., RATCLIFFE, P. J., BACHMANN, S., MAXWELL, P. H. and 
ECKARDT, K.-U. (2002) ‘Widespread hypoxia-inducible expression of HIF-2α in distinct 
cell populations of different organs’, The FASEB Journal. Federation of American Societies 
for Experimental Biology, 17(2), pp. 271–273. doi: 10.1096/fj.02-0445fje. 
 
van der Windt, G. J. W. and Pearce, E. L. (2012) ‘Metabolic switching and fuel choice 
during T-cell differentiation and memory development.’, Immunological reviews. England, 
249(1), pp. 27–42. doi: 10.1111/j.1600-065X.2012.01150.x. 
 
Woo, Y. H. and Li, W.-H. (2012) ‘Evolutionary Conservation of Histone Modifications in 
Mammals’, Molecular Biology and Evolution. Oxford University Press, 29(7), pp. 1757–
1767. doi: 10.1093/molbev/mss022. 
 
Wu, M.-Z., Tsai, Y.-P., Yang, M.-H., Huang, C.-H., Chang, S.-Y., Chang, C.-C., Teng, S.-
C. and Wu, K.-J. (2011) ‘Interplay between HDAC3 and WDR5 is essential for hypoxia-
induced epithelial-mesenchymal transition.’, Molecular cell. United States, 43(5), pp. 811–
822. doi: 10.1016/j.molcel.2011.07.012. 
 
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H., Ito, S., Yang, C., Wang, P., 
Xiao, M. T., Liu, L. X., Jiang, W. Q., Liu, J., Zhang, J. Y., Wang, B., Frye, S., Zhang, Y., 
Xu, Y. H., Lei, Q. Y., Guan, K. L., Zhao, S. M. and Xiong, Y. (2011) ‘Oncometabolite 2-
hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases’, 
Cancer Cell. Elsevier Inc., 19(1), pp. 17–30. doi: 10.1016/j.ccr.2010.12.014. 
 
Youngblood, B., Hale, J. S., Kissick, H. T., Ahn, E., Xu, X., Wieland, A., Araki, K., West, 
E. E., Ghoneim, H. E., Fan, Y., Dogra, P., Davis, C. W., Konieczny, B. T., Antia, R., 
Cheng, X. and Ahmed, R. (2017) ‘Effector CD8 T cells dedifferentiate into long-lived 
memory cells’, Nature, 552(7685), pp. 404–409. doi: 10.1038/nature25144. 
 
Zhang, L., Huang, G., Li, X., Zhang, Y., Jiang, Y., Shen, J., Liu, J., Wang, Q., Zhu, J., 
Feng, X., Dong, J. and Qian, C. (2013) ‘Hypoxia induces epithelial-mesenchymal transition 
via activation of SNAI1 by hypoxia-inducible factor -1alpha in hepatocellular carcinoma.’, 
BMC cancer. England, 13, p. 108. doi: 10.1186/1471-2407-13-108. 
 
 
